Design of a Novel Left Ventricular Restraint Device for the Treatment of Heart Failure by Marien, Alissa Denise et al.
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2008
Design of a Novel Left Ventricular Restraint Device
for the Treatment of Heart Failure
Alissa Denise Marien
Worcester Polytechnic Institute
Allen Lau
Worcester Polytechnic Institute
David Roy Sansoucy
Worcester Polytechnic Institute
Katherine Jean Soojian
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Marien, A. D., Lau, A., Sansoucy, D. R., & Soojian, K. J. (2008). Design of a Novel Left Ventricular Restraint Device for the Treatment of
Heart Failure. Retrieved from https://digitalcommons.wpi.edu/mqp-all/1398
Project Number MQP-GRG-0801 
Design of a Novel Left Ventricular Restraint Device for the 
Treatment of Heart Failure   
 
A Major Qualifying Project Report  
 
Submitted to the Faculty 
 
of the 
 
Worcester Polytechnic Institute 
 
in partial fulfillment of the requirements for the 
 
Degree of Bachelor of Science 
 
by 
 
 
_____________________ 
Allen Lau 
 
 
_____________________ 
Alissa Marien 
 
 
_____________________ 
David Sansoucy 
 
 
_____________________ 
Katherine Soojian 
 
Date: April 24, 2008 
 
Approved by:  
 
_____________________ 
Glenn Gaudette 
 
1. Heart failure 
2. Left ventricular restraint 
3. Microthreads
 i 
Abstract 
Myocardial infarction is an event that causes the death of myocytes. In an effort to 
compensate for lost functional myocytes, left ventricular remodeling may occur, causing 
adverse geometric and functional changes. If untreated, this may lead to heart failure. The 
goal of this project was to develop a left ventricular restraint device that provides 
structural support and promotes angiogenesis to treat heart failure. Proof of concept 
testing indicated that the device would promote angiogenesis and reduce dilatation.  
 ii 
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Executive Summary 
Cardiovascular disease is the leading cause of death in the United States.  More 
deaths are caused by cardiovascular disease each year than cancer, respiratory diseases, 
accidents, and diabetes combined [1]. Myocardial infarction (MI) occurs when blood 
flow through the coronary arteries is reduced, which causes damage to the heart.  
Following MI, progressive left ventricular (LV) remodeling may occur, where the heart 
enlarges and expands along with increased thinning of the heart wall [2]. The process of 
LV remodeling may cause a decrease in global cardiac function which may eventually 
lead to heart failure [3, 4].  
LV restraint devices provide structural support to prevent LV remodeling [5]. 
These devices have been shown to prevent further LV dilatation, or enlargement, and, in 
some cases, reverse remodeling has also been observed [6, 7]. Also, stem cells, growth 
factors, and biomolecules are currently being investigated for their use in the treatment of 
heart disease. Many different types of stem cells are currently being explored for their 
ability to regenerate myocardium, all with their own advantages and disadvantages [8].  
Growth factors and biomolecules have been explored for their ability to induce 
angiogenesis and prevent left ventricular remodeling [9, 10, 11, 12]. Also, biomaterials 
that are being investigated for biological applications, such as contractile polymers and 
microthreads, could potentially be used in cardiac applications. Contractile polymers are 
polymers that can contract upon application of a stimulus [13]. Biologically-derived 
fibers called microthreads have been studied for their use in the repair and regeneration of 
tendons and ligaments. These threads, made of collagen or fibrin, are useful for these 
applications because of their chemical stability, biocompatibility, and structural similarity 
to native tendon or ligament [14].    
Despite the fact that there have been advances made in the treatment of heart 
failure there are currently no devices on the market that simultaneously reverse the 
effects of left ventricular (LV) remodeling and promote regeneration of the myocardium. 
The initial goal of this project was to design, build, and test a device that improves the 
function of an infarcted heart by providing structural support, providing contractile 
assistance, and delivering a therapeutic agent. The device would be intended for patients 
with late stage III and early stage IV heart failure. 
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A restraint device was designed that incorporated polyaniline (PANI) as the major 
component. Various protocols for manufacturing PANI were performed in order to obtain 
a method that produced uniform films of PANI with the appropriate mechanical and 
contractile properties. Unfortunately, after utilizing many manufacturing protocols, 
uniform films of PANI that contracted with the application of an electrical stimulus could 
not be obtained. Due to these results, PANI did not appear to be a viable material for use 
in a contractile LV restraint device. Thus, a consensus was reached to re-evaluate the 
preliminary designs in order to select a more feasible design.  
A passive wrap restraint design that incorporates a therapeutic agent was selected. 
Collagen microthreads were chosen as the major component of the device because they 
are highly biocompatible, can be manufactured to hold proteins and/or growth factors, 
have good mechanical properties, and were readily available. In the selected design, the 
microthreads were configured in a mesh that wrapped around the ventricles of the heart. 
Additionally, platelet-derived growth factor (PDGF) was selected as the therapeutic agent 
because it promotes angiogenesis, or blood vessel formation, which would provide an 
environment conducive to myocardial regeneration. 
In order to perform preliminary testing of the design, proof of concept tests were 
conducted to confirm the device’s ability to promote angiogenesis and provide structural 
support. First order approximations were used to determine the number of microthreads 
required to produce the mesh restraint. A cell migration assay using smooth muscle cells 
(SMCs) was performed to determine the ability of the device to promote angiogenesis 
with three groups tested – PDGF coated microthreads, control microthreads, and control 
petri dishes with no microthreads. The extent of migration and proliferation of the SMCs 
in each plate was assessed by observing specific regions of the plate using an inverted 
light microscope. 
As a first approximation, it was found that 34 microthreads would be required to 
produce a mesh that provides the appropriate amount of structural support. A basic 
mechanics equation demonstrated that the mesh would reduce the dilatation of the heart. 
With the cell migration assay, a plethora of cells was observed surrounding the PDGF 
coated microthreads, while few cells were observed surrounding the control samples.  
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The results presented demonstrate that PDGF coated microthreads could be used 
to develop a LV restraint that promotes angiogenesis. Since only proof of concept testing 
was performed, future testing and development of this device is necessary before it can 
be used in a clinical setting. It is recommended that the PDGF concentration on the 
microthreads be optimized and that mechanical testing be performed on the microthread 
mesh. Also, it is necessary to test the device in small and large animal models to confirm 
its ability to promote angiogenesis and possibly deliver regenerative agents in vivo. 
Although all the desired testing could not be accomplished due to time constraints, this 
design provides a strong foundation for future development in creating a left ventricular 
restraint device that promotes angiogenesis for patients that suffer from heart failure.  
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1 Introduction 
Cardiovascular disease is the leading cause of death in the United States.  More 
deaths are caused by cardiovascular disease each year than cancer, respiratory diseases, 
accidents, and diabetes combined. Approximately 1 in 3 American adults have 
cardiovascular disease, which corresponds to an estimated 79 million people, about 8 
million of which have suffered a myocardial infarction. In 2007 alone, the estimated cost 
of cardiovascular disease was $431.8 billion USD [1]. 
Myocardial infarction occurs when blood flow through the coronary arteries is 
reduced. With a prolonged reduction in blood supply, the cells within the myocardium 
may begin to die [15]. When myocyte necrosis occurs, the function of the heart declines 
because some contractile ability is lost [3, 16]. Myocyte necrosis may induce progressive 
left ventricular (LV) remodeling, where the heart enlarges and expands along with 
increased thinning of the heart wall [2]. The process of LV remodeling eventually may 
lead to a decrease in global cardiac function and an increase in mortality [3, 4]. 
Clinical treatment following MI involves a regimen of beta-blockers, ACE 
inhibitors, and nitric oxide administration. However, the aim of these treatments is to 
increase the patient’s cardiac output by providing symptomatic relief, and therefore 
delaying disease progression. Current treatments do not prevent future cardiac events, 
including further LV remodeling, from occurring [17, 18]. Treatments and therapies are 
currently being developed to prevent LV remodeling and regenerate myocardium. LV 
restraint devices provide structural support to prevent LV remodeling [5].  These devices 
have been shown to prevent further LV dilatation and reverse remodeling has also been 
observed [6, 7].  
Stem cells, growth factors, and biomolecules are currently being investigated for 
use in the treatment of heart disease. Many different types of stem cells are currently 
being explored for their ability to regenerate myocardium, all with their own advantages 
and disadvantages [8].  Growth factors and biomolecules are being examined for their 
ability to induce angiogenesis and prevent further remodeling following myocardial 
infarction [11, 12]. 
Biomaterials that are being investigated for biological applications, such as 
contractile polymers and microthreads, could potentially be used in cardiac applications. 
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Contractile polymers are polymers that can contract upon application of a stimulus [13]. 
Biologically-derived fibers called microthreads have been studied for use in the repair 
and regeneration of tendons and ligaments. These threads, made of collagen or fibrin, are 
useful for these applications because of their chemical stability, biocompatibility, and 
structural similarity to native tendon or ligament [14].    
Despite the fact that there have been advances made in the treatment of heart 
failure, there are currently no devices on the market that simultaneously reverse the 
effects of LV remodeling and aid in the regeneration of the myocardium. The initial goal 
of this project was to design, build, and test a device that improves the function of the 
failing heart by providing structural support, providing contractile assistance, and 
delivering a therapeutic agent. However, a device that provided contractile assistance 
could not be developed within the given time and budget constraints. Therefore, the 
designs were re-evaluated to select a design that did not provide contractile assistance. 
The revised goal of this project was to design, build, and test a device that improves the 
function of the failing heart by providing structural support and simultaneously delivering 
a therapeutic agent.  
Collagen microthreads were selected as the major component of the device due to 
their ability to hold proteins and/or growth factors and their mechanical properties [19]. 
Platelet-derived growth factor (PDGF) was selected as the therapeutic agent because it 
promotes angiogenesis, or blood vessel formation, which would provide an environment 
conducive to myocardial regeneration [10, 20]. To test the device’s ability to promote 
angiogenesis, a cell migration assay was performed in order to observe the migration and 
proliferation of smooth muscle cells with PDGF coated microthreads in comparison to 
control samples. Basic mechanics calculations were used to verify that the mesh would 
reduce dilatation of the heart wall. Preliminary testing suggested that the device would 
promote angiogenesis and reduce dilatation of the heart wall. The results obtained 
demonstrated a proof of concept of the device design. 
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2 Background 
2.1 The Heart and Myocardial Infarction 
The cardiovascular system is essential to the proper functioning of the body. 
Blood transports nearly everything within the body, including oxygen, nutrients, waste 
products, and hormones. The heart is of vital importance within the cardiovascular 
system because its pumping action drives the circulation of the blood [21].  
2.1.1 Mechanisms of the Heart 
The heart wall consists of three main layers – the epicardium, myocardium, and 
endocardium. The epicardium is the outermost layer of the heart, which also contains the 
pericardium – a double layer membrane filled with fluid that allows the heart to contract 
in a relatively friction-free environment. The endocardium is the innermost layer of the 
heart that interfaces with the blood. This layer consists of endothelial cells that are 
continuous with the lining of the blood vessels. The myocardium is located in between 
the epicardium and endocardium. This layer contains the cardiac muscle cells, or 
cardiomyocytes, that perform contraction. The myocytes contract upon stimulation from 
the heart’s pacemakers – the sinoatrial node and atrioventricular node. This causes 
contraction of the right and left ventricles and subsequently leads to blood flow through 
the systemic and pulmonary circulatory systems [21]. 
The heart itself is supplied with nutrients and oxygen by the surrounding coronary 
arteries. Blood flow through these arteries occurs during ventricular diastole, or filling, 
because when the ventricles are contracting the coronary vessels are compressed. When 
stenosis, or blockage, of a coronary artery occurs, blood flow to the heart is reduced 
causing a myocardial infarction [21]. 
2.1.2 Myocardial Infarction (MI) 
Myocardial infarction (MI) is caused by ischemia of the myocardium as a result 
of reduced blood flow through the coronary arteries. Ischemia occurs when there is an 
imbalance between the nutrient and oxygen supply to the tissue and the demands of the 
tissue [15].  Immediately following ischemia, myocardial stunning occurs. The myocytes 
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enter a state of “hibernation,” where the cells continue to survive but are unable to 
contract because of deficient arterial flow. When myocardial stunning occurs, the 
myocytes appear to down-regulate their metabolism, allowing them to survive with 
insufficient nutrients. The cells may recover their contractile function if blood flow is 
restored via reperfusion [22]. Cell death, or necrosis, begins to occur in as little as 15 
minutes, with complete necrosis occurring in 4-6 hours if blood flow is not restored or 
therapeutic measures are not taken [15]. When necrosis occurs after MI, the process of 
LV remodeling may begin in order to normalize the function of the left ventricle. 
2.1.3 Process of LV Remodeling 
LV remodeling is the process by which the size, shape, and function of the left 
ventricle are altered by mechanical, neurohormonal, and other factors [2]. Remodeling 
can occur due to pressure overload, which is caused by stenosis, hypertension, or dilated 
cardiomyopathy, or volume overload, which is caused by valve regurgitation or 
myocardial infarction [18]. After myocardial infarction, the process of remodeling is 
stimulated by increased loading conditions due to a loss of functional myocardium [2].   
Ventricular remodeling occurs most frequently after transmural infarctions that 
span the thickness of the ventricular wall and with infarctions in the anterior apical region 
of the heart because this region has the thinnest wall and greatest curvature. Some factors 
that affect the extent of remodeling are infarct size, patency of the arteries, and 
ventricular loading conditions [3, 4, 23]. Among studies, there is a general consensus that 
remodeling begins to occur within the first 24 hours following MI [2, 18, 24]. However, 
LV remodeling does not always occur after MI – one study noted that only 46% of 
patients who suffered myocardial infarction experienced remodeling and 20% of the total 
number of patients experienced progressive remodeling [4]. Progressive remodeling is 
the term used to describe cases where remodeling continues to occur longer than three to 
six months post-infarction [3, 4]. LV remodeling can result in a vicious cycle that puts 
patients at risk for congestive heart failure, myocardial rupture, aneurysm, and ultimately 
leads to death [23]. The process detailed below describes the events that occur during 
progressive remodeling. 
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Changes in Infarct Zone 
Immediately following myocardial infarction, necrotic tissue within the infarct 
zone is absorbed by macrophages. The infarcted region is most vulnerable to forces in the 
time after necrotic tissue is absorbed, but before collagen reinforcement [23]. It is during 
this time period that the infarcted region can expand and enlarge, leading to thinning and 
dilatation [2, 3, 23]. Infarct expansion is due mainly to the rearrangement and stretching 
of myocytes. Rearrangement of myocytes occurs as adjacent muscle bundles slip due to 
the degradation of intracellular collagen struts as a consequence of a reduced number of 
myocytes. Cell stretch occurs due to an increase in sarcomere length [2, 23, 24]. 
Once collagen deposition occurs and scar tissue begins to form, the infarcted 
region becomes more resistant to deformation [23]. This allows the infarct to better resist 
stresses, which eventually halts infarct expansion [3].   
 
Changes in non-infarcted myocardium 
In addition to infarct expansion, the non-infarcted myocardium also undergoes 
structural changes post-infarction in response to different loading patterns [2, 4, 16, 23]. 
After infarction, stroke volume is decreased due to a reduced number of functional 
myocytes in the infarcted region. This places a burden on the functional myocardium in 
the non-infarcted region [3, 16]. As a compensatory mechanism, the non-infarcted 
myocardium undergoes hypertrophy, or enlargement, to maintain stroke volume and 
stabilize contractile function [16, 23]. Enlargement of the non-infarcted region is a cyclic 
process – the process begins in order to maintain stroke volume, but enlargement causes 
increased wall stresses, which cause further enlargement [23].   
The mechanism of hypertrophy depends on the type of overload that occurs. With 
volume overload, which is a result of increased diastolic pressure, hypertrophy occurs by 
the addition of new sarcomeres and fiber elongation. With pressure overload, which is a 
result of increased systolic wall stresses, hypertrophy occurs due to the addition of 
parallel myofibrils. Regardless of the type of hypertrophy, the result is the enlargement of 
the non-infarcted region [3]. 
Numerous studies note that compensatory hypertrophy causes an initial 
improvement in ventricular function, but with further expansion, function declines [3, 4, 
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25]. It has been noted that within approximately two to four weeks, stroke volume returns 
to normal due to hypertrophy of non-infarcted myocardium, however function begins to 
decline thereafter and deterioration is evident approximately six months post-infarction 
[4, 25].   
 
Changes in LV Performance 
Although progressive remodeling initially results in an improvement of 
hemodynamics, such as increased stroke volume, the long-term effects of remodeling 
result in decreased regional and global performance [3, 4]. The heart undergoes 
geometrical changes including increases in volume, mass, and changes in shape, where 
the heart becomes more spherical and less elliptical [18]. Along with the alterations in 
ventricular geometry, expansion produces elevated left ventricular end-diastolic pressure, 
increased end-diastolic volume, increased end systolic volume, reduced ejection fraction, 
increased systemic vascular resistance, increased right atrial pressure, and decreased 
stroke volume [4, 16, 25]. A summary of the mechanisms and results of progressive LV 
remodeling can be seen in Figure 1 below. These hemodynamic changes increase 
mortality by increasing the potential for heart failure [25].   
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Figure 1: Overview of LV Remodeling 
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2.1.4 Heart Failure Classifications 
The New York Heart Association (NYHA) has developed a classification system 
for the stages of heart failure. This classification system describes four major stages. In 
classes I and II, the patient is said to have mild heart failure. Patients in class I do not 
have limitations in physical activity and do not experience fatigue or shortness of breath 
during normal activity. Patients in class II experience slight limitations in physical 
activity and ordinary physical activity may cause fatigue or shortness of breath. In class 
III, patients experience marked limitations in activity and ordinary activity causes fatigue.  
Class IV patients have severe heart failure and are unable to carry out any physical 
activity without discomfort [26]. These classifications established by the NYHA will be 
referred to throughout this paper. 
2.1.5 Current Treatments for LV Remodeling and MI 
Reperfusion, thrombolysis, angioplasty, and stenting are treatments typically 
performed after MI to salvage myocardium, improve patency of arteries, and restore 
blood flow to the infarcted area [2]. Following these therapies, patients are normally 
treated with ACE inhibitors, beta-blockers, and/or nitroglycerin.   
Current treatments and therapies prescribed to patients to treat MI and LV 
remodeling are aimed at increasing cardiac output by providing symptomatic relief [18]. 
The drugs and therapies described in this section simply delay disease progression, but do 
not prevent future events from occurring [17]. 
 
ACE Inhibitors 
Angiotensin converting enzyme inhibitors (ACE inhibitors) have been shown to 
increase stroke volume, increase ejection fraction, and reduce LV volumes in patients 
following MI compared to patients treated with placebos [2, 17, 27]. ACE inhibitors act 
by preventing the conversion of angiotensin I to angiotensin II. Angiotensin II is a 
vasoconstrictor that raises arterial blood pressure. Thus by preventing production of 
angiotensin II ACE inhibitors have vasodilating effects and result in lower blood pressure 
[21]. ACE inhibitors attenuate ventricular enlargement, dilatation, and thinning by 
ventricular unloading and have been shown to offer long-term survival benefits to 
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patients following MI [2, 16, 17, 28]. Many experts agree that for ACE inhibitors to 
provide the best benefit, they should be administered very early following infarction 
(possibly as early as one week) [2, 27].   
Although ACE inhibitors offer beneficial results, they can also cause harmful 
effects. Since ACE inhibitors are vasodilators they cause hypotension, which may 
decrease myocardial perfusion resulting in additional myocardial apoptosis [2].   
 
Beta-Blockers 
Beta-adrenergic receptor blockers, commonly known as beta-blockers, are often 
used in conjunction with ACE inhibitors to provide complimentary effects [2]. Beta-
blockers have been shown to improve ejection fraction, reduce left ventricular end-
systolic volume, and subsequently reduce mortality when used concomitantly with ACE 
inhibitors [17, 27]. A disadvantage of beta-blockers is that they promote hypotension, 
which may reduce myocardial perfusion, similar to ACE inhibitors [2]. 
 
Nitric Oxide 
A current treatment available for myocardial infarction is nitric oxide. At first 
nitric oxide was solely used to increase vasodilatation. However, it was later found to 
improve the function of the myocardium [29].  It has also been shown by Liu et al. that 
nitric oxide decreases infarction size [30]. Tests of the effects of nitric oxide on dogs 
found that it preserved coronary vasodilatation, inhibited neutrophil accumulation, and 
reduced myocardial necrosis. This treatment has been proven most effective when 
administered immediately post-infarction [30].      
2.2 Left Ventricular (LV) Restraints 
 Myocardial infarction may initiate the cyclic processes of progressive ventricular 
remodeling which may eventually result in chronic heart failure. Left ventricular 
remodeling attempts to preserve the cardiac output in an infarcted heart. Early on the 
remodeling process is beneficial, but over time can become detrimental. The cessation of 
adverse geometrical changes may help preserve the function of the heart. LV restraints 
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are devices that are designed to prevent further enlargement of a patient’s heart and thus 
improve the patient’s overall cardiac health.  
2.2.1 Biologically-derived Restraints 
One of the first types of LV restraints was a biological restraint comprised of a 
patient’s own skeletal muscle. These early biologically-derived restraints were successful 
in that the materials needed were taken from the patient’s body so that a foreign body 
response was avoided.  
 
Dynamic Cardiomyoplasty 
 Dynamic cardiomyoplasty was first introduced by Carpentier and Chachques in 
1985. It is a surgical technique that was developed as a treatment for dilated 
cardiomyopathies and late-stage heart failure. In the procedure, a skeletal muscle flap, 
typically taken from the latissimus dorsi, is removed from the patient and then secured 
around the heart. A few weeks after the surgery, the muscle flap undergoes a conditioning 
regimen using specialized stimulator devices. The reported benefits of the procedure 
include increased ejection fraction, improved LV stroke work index, and decreased New 
York Heart Association (NYHA) functional class. Furthermore, 6 months after the 
operation, more than 75% of the surviving patients had improved by one or more NYHA 
class [31].  
 Despite the seemingly positive results of the surgery, the technique has not 
become widely used due to negative postoperative and long-term effects. Immediate and 
long-term deaths following the procedure have been attributed to ventricular failure and 
arrhythmia. According to a Medtronic database, procedural deaths occurred in 36% of 
patients in NYHA class IV and in 15% of those in class III. Another potential short-term 
complication is that the ischemic skeletal muscle flap fails to contract upon electrical 
stimulation [31]. Other long-term concerns involve the duration of the muscle flap’s 
functioning. Similarly, it has been stated that the short-term clinical improvements of 
dynamic cardiomyoplasty were followed by a gradual decrease in cardiac performance 
because over time the muscle flap atrophies and is replaced by fat [32].   
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 Even though the procedure’s long-term efficacy may be questionable, it 
nonetheless has served as an important learning tool. Aside from the obvious support of 
LV systolic function from the muscle’s contraction, the muscle wrap acts as an elastic 
restraint. The elastic restraint limited cardiac dilatation, which aided reverse remodeling 
and prevented further enlargement [31]. In a canine study it was observed that a non-
stimulated latissimus dorsi muscle preserved heart function compared to controls [33]. 
Such studies encouraged investigation into passive cardiomyoplasty devices made of 
biomaterials that would attenuate LV dilatation.  
2.2.2 Passive Biomaterial Restraints 
Despite the advances that have been made with biologically-derived restraints, 
they do have limitations, which prompted the development of biomaterial based 
restraints.  Currently, these restraints are being evaluated for prevention of cardiac 
dilatation.  There are several different types of biomaterial based restraints that are being 
developed.     
 
CorCap™ Cardiac Support Device (CSD) 
 The Acorn Cardiovascular CorCap™ CSD is a polyethylene terephthalate (PET-
polyester) mesh that encircles the heart from the atrioventricular groove to its apex as 
shown in Figure 2. PET-polyester provides the necessary mechanical properties, is 
resistant to biodegradation, interfaces easily with the heart’s surface and its physical and 
mechanical characteristics can be controlled. The CorCap™ is designed to provide 
passive pressure on the LV. This prevents further dilatation and adverse remodeling by 
reducing chronic dilatation of end-diastolic volume, ventricular wall stress, myocardial 
stretch, and eventually promotes reverse remodeling. The device provides a slightly 
greater amount of pressure on the heart at the end of diastole than at the end of systole 
and it is not specifically intended to provide assistance during systolic contraction. 
Furthermore, CorCap’s design allows for bidirectional compliance, with more 
compliance available in the longitudinal direction (apex to base) than in the 
circumferential direction. This facilitates the gradual reshaping of the heart from 
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spherical to its natural ellipsoid shape [34]. It is available in six standard sizes and the 
final fitting is done by the surgeon [35]. 
 
Figure 2: CorCap™ CSD
 
(with permission from Acorn Cardiovascular) [36] 
 
The implantation involves a sternotomy and typically requires the patient to be on 
full cardiopulmonary bypass (CPB). The device is adjusted to fit snugly around the 
ventricles and reduce the diameter of the heart by 5-10% as measured by transesophageal 
echocardiography. Due to the invasiveness of the surgery, the implantation of the device 
is carried out mainly in patients with NYHA chronic heart failure class from late II to 
early IV. Patients in class IV heart failure that receive continuous medication or 
mechanical support, as well as those with other medical conditions, may be at too high of 
a risk to undergo the procedure and may not fully benefit from the CSD [35]. Additional 
cardiac procedures may be performed concurrently with CorCap™ implantation. 
Functional mitral regurgitation (MR) is a typical result of the increased spherical shape of 
the LV and it results in further mechanical burden on the LV [37]. Consequently, surgical 
implantation of the CorCap™ is usually accompanied by mitral valve (MV) surgery. 
Coronary artery bypass graft (CABG) is another procedure that is typically carried out in 
patients receiving CorCap™ [35]. Average total operative times reported for the 
CorCap™ initial safety studies include: 2.3 hours ± 0.6 hours for CorCap™ only and 3.5 
hours ± 1.2 hours for concomitant cardiac procedures [38]. 
The efficacy of the CorCap™ has been assessed by many different methods in the 
months and years of postoperative patient monitoring. In the initial safety studies it was 
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observed that many patients experienced significant decreases in LV end-diastolic 
dimension (LVEDD) and an increased LV ejection fraction (LVEF) with changes 
observed as early as 3 months post-infarction. The safety studies also reported a decrease 
in the MR classification, even in patients who did not undergo concurrent mitral valve 
surgery. More holistic long-term improvements included a decrease in NYHA heart 
failure class and a better quality of life as indicated by questionnaires [38]. Although 
long-term data from the Acorn Trial, a large randomized multicentered trial of 300 
patients, is still being collected and evaluated, the initial results support many of the 
above-mentioned cardiac changes. However, it was reported that there was no significant 
survival difference at the one-year follow-up between the Cardiac Support Device and 
control groups, even though the CSD treatment group was significantly less likely to 
require a major cardiac procedure [6].   
In addition to changes in global heart function and patients’ well being, several 
animal studies have reported changes at the cellular and biomolecular levels as a result of 
long-term CSD therapy. In a canine model of heart failure, it was demonstrated that long-
term CSD therapy was associated with improved cardiomyocyte contraction and 
relaxation, down regulation of stretch response proteins, and attenuation of 
cardiomyocyte hypertrophy compared to the controls [7]. Additionally, other studies have 
shown that CorCap™ treatment leads to less interstitial fibrosis, greater myocardial 
capillary density, and reduced myocyte apoptosis [38]. The above-mentioned studies 
provided insight into the mechanisms of improvement that may be responsible for the 
reverse remodeling observed in clinical trials. 
Among the LV restraints investigated thus far, the CorCap™ appears to be the 
furthest along in terms of clinical trials. The CorCap™ received CE mark approval in 
Europe in 2001 (the equivalent to the US’s FDA) and has been available to a small 
number of hospitals in a Limited Market Release Surveillance Study (LMRSS) [38]. The 
device is currently not FDA approved and is limited to investigational use in the US [39, 
40]. 
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HeartNet™ Ventricular Support System 
The Paracor Medical HeartNet™ is a passive circumferential restraint made from 
a superelastic nitinol mesh shown in Figure 3. It is similar to the CorCap™ in that it 
surrounds both ventricles, but it does not cover the apex of the heart. The nitinol mesh 
exerts a small but continuous force on the heart to prevent adverse LV remodeling. 
Nitinol is used because of its physical properties, its proven biocompatibility in human 
implants, and its superelastic properties which allow it to exert a nearly constant 
restraining force over a large range of strain. The above-mentioned properties reduce the 
possibility of constricted coronary vessels and ensure that force is still applied even if the 
heart decreases in size [41]. 
 
Figure 3: Paracor HeartNet™ (with permission from Paracor Medical, Inc.) [42] 
 
 The implantation is minimally invasive, involves general anesthesia, and 
operative times have averaged under 60 minutes with many as low as 30 minutes. A 
small incision is typically made in the 6th or 7th intercostal space of the thoracic cavity 
and the device is delivered in compressed form by a proprietary delivery tool. The mesh 
is then expanded and elastically conforms to the heart without the need for sutures. 
Imaging is then utilized to ensure proper placement. Since the surgery is perceived to be 
low risk, the patients selected for the HeartNet™ trials generally had a slightly better 
initial NYHA functional status than the CorCap™ patients [41].    
The HeartNet™ is not FDA approved and is in early clinical trials. Early canine 
and bovine experiments have established the safety and feasibility of the device. An 
initial clinical trial involved 20 patients, 10 in the US and 10 in Europe, and decreases in 
dilatation, functional status, and exercise capacity were observed. Importantly, the initial 
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human trial reported no signs or symptoms of constricted coronary vessels. There were 
no operative or late deaths in the study and the results were favorable, but have not been 
presented in detail [41].  
 
Myosplint®
 
The Myocor™ Myosplint® is a passive LV restraint of the “nut and bolt” type as 
shown in Figure 4. It is designed to correct the LV spherical shape that is characteristic of 
patients with advanced heart failure. It consists of an implantable transventricular splint 
and two epicardial pads on each end of the splint. The splint bisects the left ventricle and 
upon applying tension, it applies forces such that the LV takes on a more normal shape. 
The splint is made from 1.4mm diameter braided polyethylene and is coated with 
expanded polytetrafluoroethylene (ePTFE). The epicardial pads are covered with a 
polyester fabric [5]. 
 
Figure 4: Myosplint® Components and Cardiac Configuration (with permission from Elsevier) [43]  
 
Typically, three splints are implanted in an open-chest procedure by a proprietary 
delivery tool. The three splints are equally spaced between the apex and the base of the 
LV. Coronary vasculature is identified during implantation in order to avoid damage or 
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restriction of coronary vessels. Epicardial echocardiography is used to place the splints 
and ensure the avoidance of papillary muscles. A measurement and tensioning instrument 
adjusts the device to produce a 20% reduction in wall stress. In a non-randomized clinical 
safety trial, it was reported that implantation typically took from 40-50 minutes [44]. 
Preclinical canine studies established the safety of the device at 180 days. No pad 
piercing of the ventricular wall, device migration, or thrombus formation was observed 
[5]. The significant results of one human clinical study included improvements in NYHA 
heart failure classification, significant reductions in LVEDV and LVESV, and increased 
LVEF [44].  
The study of the Myosplint led to the development of the Myocor™ Coapsys® 
device to treat functional MR in a minimally invasive procedure [44]. The 
aforementioned study did not indicate whether more trials were planned or are being 
conducted with the Myosplint®.  
 
Coapsys® Annuloplasty System 
The Myocor™ Coapsys® device is designed to treat mitral annular dilatation and 
papillary muscle displacement. Its mechanism of action can be seen in Figure 5. 
Ventricular dilatation in dysfunctional LVs results in remodeling of the mitral valve, 
which causes mitral regurgitation (MR). The subsequent MR is commonly considered to 
be one of the initial causes of heart failure and is an ongoing condition during the disease 
[45]. 
The Coapsys® device is similar to the Myosplint® in terms of the polymers used. 
It is a passive device that contains two epicardial pads connected by a transventricular 
polymer splint. The posterior side of the device consists of a rig, which holds two 
posterior epicardial pads: a superior and inferior one. The superior pad creates a shape 
change at the MV level to correct the valve’s poor closure and the inferior pad creates a 
change at the papillary muscle level. The placement ensures that the splint passes 
between the papillary muscles and below the valve leaflets. Once in place, the device is 
then tightened by drawing the anterior and posterior pads together and then fixing the 
anterior pad to the polymer splint [45].  
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Figure 5: Coapsys® Mechanism of Action (with permission from Elsevier) [46] 
 
The surgical procedure for the implantation of the Coapsys device does not 
require CPB [47]. An incision is typically made along the sternum and the device is 
positioned by hand with a proprietary delivery device and vacuum assistance. 
Verification of the placement is done with handheld echocardiography [45]. The sizing of 
the device is determined by real-time color flow Doppler imaging to quantitatively assess 
the MR and a proprietary device is used to shorten the splint until MR is eliminated or a 
maximum shortening of 35% has been reached [47].  
The results of the few clinical safety and feasibility studies performed were 
promising. In one study, 19 patients with functional MR and coronary artery disease were 
selected to undergo CABG and Coapsys® device implantation. Mean LV chamber 
diameter, sphericity index (ratio of LV short-axis to long-axis dimensions), and MR 
grade were significantly reduced [47]. Another study reported also reported decreased 
NYHA classification. Importantly, the aforementioned results were sustained through 1-
year follow-up [45]. At this point randomized clinical trials of Coapsys® are ongoing. 
2.3 Left Ventricular Assist Device (LVAD) and LV Unloading 
 Unloading the dysfunctional LV can often lead to some improvement in function. 
Left ventricular assist devices (LVADs) typically consist of electrically powered pumps 
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that serve to transport blood from the LV to the ascending aorta, thereby reducing the 
workload of the dysfunctional LV [48]. LVADs have become a mainstream bridge to 
cardiac transplant [49]. However, in a small subset of LVAD recipients, about 5%, it was 
observed that the patients could be weaned off the device with nearly normal cardiac 
function. Consequently, LVADs have recently been used as bridges to recovery to restore 
basic cardiac function without subsequent transplantation [48]. 
 LVADs provide a significant volume and pressure unloading of the LV and 
therefore normalizations of neurohormonal and cytokine activities have been reported. 
Several reports have further documented the recovery of native LV function after long-
term LVAD support [48]. The reported results of long-term LVAD support were 
significant normalization of cardiomyocyte geometry, cellular level changes that were 
associated with reductions in LV dilatation and mass, and the normalization of expression 
and function of proteins involved in calcium handling, cellular hypertrophy, cell cycling, 
and apoptosis [50]. However, a number of properties including abnormal extracellular 
matrix metabolism, increased tissue angiotensin levels, and myocardial stiffening did not 
improve with LVAD support [51]. 
2.4 Biomaterials for Myocardial Infarction  
 Researchers have been exploring the possibilities of using biomaterials for the 
treatment of heart failure for over ten years [52]. Different biomaterials, including 
contractile polymers, have been investigated to create heart patches and LV restraints. A 
biomaterial must exhibit appropriate characteristics for its intended use since it is 
ultimately going to be implanted in humans. Biomaterials must be biocompatible, wear 
resistant, non-thrombogenic, and possess appropriate mechanical strength.  
2.4.1 Heart Patches 
 One type of treatment that is currently being developed is the use of heart patches 
or grafts to provide structural support and deliver treatments. The foundation of the heart 
patch or graft is used for mechanical strength. The porous nature of the scaffold makes it 
possible for a therapeutic agent, such as stem cells, drugs, proteins, or growth hormones, 
to be seeded onto it for various applications.  In other cases, the scaffold can be implanted 
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without a therapeutic agent and used to promote cellular interactions. Some scaffolds that 
have been researched include extra cellular matrix (ECM), fibrin glue, polyester urethane 
urea (PEUU), and poly-glycolide-co-caprolactone (PGCL) [53, 54, 55, 56, 57, 58, 59, 
60].  
 
Extracellular Matrix (ECM) 
 ECM is a biomaterial proven to be useful in many kinds of biological 
applications. ECM is made out of animal tissue, which consists of collagens, elastins, 
proteoglycans, and adhesive proteins such as fibronectins and laminins. Due to the fact 
that ECM is taken from animal tissue it is highly biocompatibility and has a mechanical 
strength similar to that of human tissue. Because ECM has properties similar to native 
tissue it can also regulate cell interactions and act as a local reservoir for developing cells 
due to its porosity [53].   
 Recent studies using ECM as a heart patch for the treatment of heart failure have 
shown promising results.  In a canine study, a heart patch derived from ECM was shown 
to significantly improve heart function in infarcted regions. This study also explored the 
possibility of replacing the traditionally used Dacron heart patch with the biological ECM 
patch. Dacron is a FDA approved biomaterial that exhibits some biocompatibility and 
provides appropriate mechanical properties [61]. Similar to that of Dacron, ECM 
provides appropriate mechanical support. ECM also performs additional functions such 
as serving as a place for cardiomyocytes to anchor to and contracting in sync with the 
native myocardium. It is also important to note that ECM has been approved by the Food 
and Drug Association (FDA) [61].   
 
Fibrin Glue  
 Another biomaterial that has been used as a heart patch is fibrin glue. Fibrin glue 
has received a lot of attention in biological applications due to its superior cell retention 
and cell transport survival abilities. There are many scaffolds that possess appropriate 
mechanical properties but may not be able to house or transport cells efficiently. Fibrin 
glue has both of these traits and has been shown in recent studies to be useful in treating 
cardiac diseases. By placing the fibrin glue scaffold on an infarcted area, cells seeded on 
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the scaffold will have a higher chance of staying attached to the infarcted region. Another 
attractive trait of fibrin glue is that it can be injected as a liquid and will form a scaffold 
in vivo. Therefore, the fibrin glue scaffold can be used in minimally invasive procedures 
[54].    
 The use of fibrin glue as an injectable scaffold to treat heart failure has been 
investigated in rats. Fibrin glue scaffolds seeded with skeletal myoblasts were tested to 
determine if the cells could survive on the scaffold. Skeletal myoblasts were able to 
adhere to the scaffold, while surviving and proliferating. When the fibrin glue scaffolds 
were implanted onto the infarcted myocardium of rats the scaffolds improved heart 
function. However, the scaffold did not retain the skeletal myoblasts upon injection. 
Without cells seeded on the scaffold, it still was still able to enhance myocyte growth 
possibly due to increased neovascularization promoted by the fibrin glue, which may 
have promoted cell migration and proliferation. Therefore, it seemed that when the fibrin 
glue turned into a semi-solid, it acted as a temporary extracellular matrix for cellular 
proliferation [62]. 
 Based on this article and other literature, fibrin glue has shown potential to serve 
as a scaffold for cellular treatment of heart failure. Similar to extracellular matrix, fibrin 
glue is also FDA approved. Additionally, it is biocompatible and does not elicit an 
inflammatory response, foreign body reaction, necrosis, or extensive fibrosis.  
 
 
Polyester Urethane Urea (PEUU) 
 Polyester urethane urea (PEUU) is another promising biomaterial that may be 
used as a heart patch. Unlike the other scaffolds previously described, PEUU is a 
biodegradable polymer. In theory, a biodegradable patch will allow the heart to gradually 
repair itself so that it will no longer require a supporting patch. As the heart patch 
degrades it will be replaced with healthy myocardium.  
There have been several studies that have demonstrated use of this patch in vivo. 
Heart patches tested in rats preserved LV geometry, demonstrated growth factor 
expression, and improved contractile function relative to non-treated rats. The PEUU 
patch was found to degrade over a period of eight weeks and was replaced with smooth 
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muscle bundles, which increased wall thickness and compliance. The results of this study 
showed that the patch increased temporary mechanical support while healthy tissue was 
regenerated in the infarcted region [55].       
 Other studies have also confirmed that a biodegradable PEUU patch can improve 
heart function, preserve LV geometry, and provide temporary mechanical support to the 
infarcted heart. Additionally, it has been shown that PEUU is biocompatible, permits 
cellular interaction, and promotes endothelialization with minimal inflammation [56, 57].  
 
Composite Scaffolds 
 Many studies have explored the possibilities of combining multiple biomaterials 
to make a composite scaffold. By doing so, researchers can combine the advantages of 
multiple biomaterials to create a scaffold that best fits their needs. One example of a 
composite scaffold was made by Ameer and Langer by combining fibrin gel and 
polyglycolic acid (PGA) seeded with freshly isolated pig chondrocytes. This scaffold was 
made for targeted cell therapy and therefore required appropriate biodegradation, 
mechanical strength, and the ability to hold cells. In this case, the fibrin gel was used for 
its ability to anchor cells while the PGA acted as the drug-delivering unit by releasing the 
cells upon degradation [63].  
 Biodegradable scaffolds are an area of research that has been heavily investigated. 
PGA, PLA (polylactic acid), and the copolymer of the two (poly(DL-lactic-co-glycolic 
acid)), have been used to make biodegradable heart patches. Both polymers are 
biocompatible, possess good mechanical properties, and are easy to handle. However, 
PLA and PGA are highly hydrophobic and in turn, do not demonstrate good cell-seeding 
properties. On the other hand, other biomaterials, such as collagen, have good cell 
interactions but poor mechanical strength. Consequently, PLGA and collagen sponges 
have been combined to produce novel scaffolds that possess the advantageous properties 
of both biomaterials [58].   
 Another polymer that has received a lot of attention is poly-glycolide-co-
caprolactone (PGCL).  PGCL is biodegradable and has an extremely low immunogenic 
response in humans [59]. Piao et al. have combined gelatin mesh, collagen gel, alginate, 
PGA, poly-L-lactide fabric, and PGCL to make a composite scaffold as part of a heart 
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patch for the treatment of heart failure. In addition, they seeded the scaffold with bone 
marrow derived mononuclear cells (BMMNC). By combining these biomaterials, a 
scaffold was created that has good elastic properties, good mechanical properties, and 
promotes cellular interaction.  
2.4.2 Contractile Polymers 
 Contractile polymers are relatively new areas of research and therefore there is 
limited information regarding their use in heart patches in biological applications. 
Generally, contractile polymers are used in commercial applications such as light 
emitting diodes (LEDs), battery electrodes, and sensors [60]. However, the possibility of 
using these polymers to treat heart failure has been explored in a small number of studies. 
Contractile polymers may be able to aid in heart contraction, which would reduce the 
heart’s workload and provide an opportunity for regeneration, similar to a LVAD.   
 
Polyaniline (PANI)  
 One of the most promising contractile polymers is polyaniline (PANI) because of 
its unique properties such as controllable electrical conductivity, environmental stability, 
and rich redox chemistry [64]. Nevertheless, there are many obstacles to overcome in 
order to use this polymer in vivo including addressing the issues of biocompatibility, 
solubility, and processibility. Recent studies have investigated the possibility of using 
PANI for biological applications. 
 Huang et al. have synthesized a tri-block copolymer of PANI and PLA (PLA-
PANI-PLA), which retains the contractile properties of PANI, but also incorporates the 
biodegradable properties of PLA. Making PANI biodegradable is very beneficial for 
biological applications because this would help eliminate potential long-term 
biocompatibility issues. This copolymer has the potential to promote cell attachment and 
proliferation, although in vivo experiments have not yet confirmed the effects of the 
polymer on living systems [60]. 
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Other Contractile Polymers 
 Polythiophene, polypyrrole, and polyfuran are three other contractile polymers 
used in commercial applications similar to PANI. However, there has been limited 
research done with these polymers for cardiac applications. On the other hand, research 
has been conducted to determine their biocompatibility and potential use in stimulating 
the brain in neurodegenerative diseases [13]. 
Polypyrrole has been researched for use in applications dealing with neural 
disorders. The biocompatibility and cellular interaction of polypyrrole have been tested 
with neural tissue. Effective electrical stimulation of polypyrrole can help repair damaged 
neural tissue, by causing a chain of chemical signals to induce tissue regeneration [13]. 
Polythiophene has shown to be biocompatible, non-toxic and easily fabricated. 
Due to its biocompatibility, polythiophene has been shown to retain endothelial cells. 
When polythiophene is immersed in a solution of endothelial cells it still exhibits its 
electrocontractile characteristics [65].  
2.4.3 Microthreads 
Microthreads are biologically-derived thin fibers, generally made of either fibrin 
or collagen. Over the last few years, microthreads have been investigated for use in the 
repair and regeneration of tendons and ligaments. These threads are useful for these 
applications because they are chemically stable, biocompatible, and are structurally 
similar to native tendon and ligament. Additionally, these threads can be bundled together 
to improve their mechanical properties [14].    
 
Collagen Microthreads    
 Collagen microthreads can be derived from a number of biological sources 
including rat tails and bovine tendons. They can be made from either soluble or insoluble 
type I collagen. Generally, they have very good mechanical properties when bundled, 
braided, or cross-linked together.  However, collagen microthreads do not sufficiently 
promote cell migration, which leads to inadequate tissue in-growth from the wound site. 
Research has been focused on improving cell migration onto microthreads using growth 
factors, proteins, and cells. Depending on how the microthreads are cross-linked and 
 24 
bundled they can have ultimate tensile strength (UTS) values ranging from ~1MPa to 
about 40MPa, elastic modulus values ranging from <10MPa to 250MPa, and strain 
values ranging from 0.1 to 0.4 [66]. Biodegradation rates can also vary from weeks to 
multiple years depending on the chemical structure of the microthreads.  
 
Fibrin Microthreads 
 Fibrin microthreads are highly biocompatible with properties similar to native 
tendon and ligament. However, the mechanical strengths of fibrin microthreads are lower 
than those made of collagen. Depending on how they are cross-linked, fibrin 
microthreads have UTS values ranging from 1MPa to 8MPa, elastic modulus values 
ranging from 25MPa to 110MPa, and strain values from 0.2 to 0.3. Fibrin microthreads 
have a biodegradation rate of about a week and are being studied for their superior cell 
migration properties [19].   
A summary of the advantages and disadvantages of the biomaterials discussed in 
this section can be seen in Table 1. 
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Table 1: Summary of Biomaterials 
 PROS CONS 
Heart Patch Scaffold 
ECM • High biocompatibility 
• Appropriate mechanical 
strength 
• Regulates cell 
interactions 
• FDA approved 
• Could provoke 
immunogenic response 
• Non-biodegradable 
Fibrin Glue • Superior cell retention 
• Minimally invasive 
implantation procedure 
• Provides structural 
support  
• FDA approved 
• Biocompatible  
• Non-biodegradable 
PEUU • Biodegradable 
• Provides appropriate 
mechanical support 
• Promotes cellular 
interactions 
• Could provoke 
immunogenic response 
• Not FDA approved 
Composite Scaffolds • Combines advantages of 
different biomaterials 
• Limited research 
Contractile Polymers 
PANI • Can be biocompatible 
• Can be biodegradable 
• Controllable electrical 
conductivity  
• No long term studies 
 
Polypyrrole • Studies have been done 
in vivo 
• Can be biocompatible 
• Can promote cellular 
interaction 
• No long term studies 
Polythiophene • Can be biocompatible 
• Able to anchor cells 
• No long term studies 
Microthreads 
Fibrin Microthreads • Variable mechanical 
properties (UTS ranging 
from 1MPa to 8MPa, 
elastic modulus ranging 
from 25MPa to 
110MPa, strain ranging 
from 0.2 to 0.3) 
• No long term studies 
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• Biodegradable within 
the time frame of weeks 
to years 
• Properties similar to 
native tendon and 
ligament 
• Low cost 
• High cell migration 
rates 
• Easily produced 
Collagen Microthreads • Variable mechanical 
properties (UTS ranging 
from 1MPa to 40MPa, 
elastic modulus ranging 
from 10MPa to 250 
MPa, strain ranging 
from 0.2 to 0.4) 
• Biodegradable within 
the time frame of 1 
week 
• Properties similar to 
native tendon and 
ligament 
• Easily produced 
• No long term studies 
• Higher cost than fibrin 
microthreads 
• Cell migration may be 
difficult 
2.5 Regenerative Therapies for Infarcted Myocardium 
Regenerative medicine is currently a hot topic in the medical world, which could 
revolutionize medicine. However, because regenerative medicine is still undergoing vast 
research and scrutiny there are many different methods for regenerative therapy that are 
being explored for treatment of heart failure. 
 
2.5.1 Cell based therapies 
 The therapies and drugs most commonly used to treat heart failure have only 
been shown to maintain the damaged state of the heart or keep it from progressively 
worsening. In the last several years however, the possibility of stimulating regeneration 
of damaged tissue has been at the forefront of research. This is due to the fact that 
triggering the body to heal itself could still allow for beneficial treatment while avoiding 
some of the greatest barriers facing the field of biomaterials today. The research that has 
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been done over the past several years in the field of regenerative medicine and in 
particular cardiovascular regeneration has been rather promising. The ability to implant 
cells of various types into the damaged region and have them promote myocardial 
regeneration as well as improve cardiac function has been demonstrated in both pre-
clinical and clinical studies. However, it is crucial to note that all of the various cell types 
that can be used to regenerate the myocardium are not without complications. Technical 
worries, as well as ethical issues are different and vary in degree for the different types of 
cells explored for therapeutic purposes. For these reasons it is important to explore each 
of the different researched cell lines and their individual pros and cons, a summary of 
which is provided in Table 2. 
 
Embryonic Stem Cells 
One type of cell that is being explored for use as a cell-based therapy is the stem 
cell. Stem cells are characterized by their ability to be capable of self-renewal, 
differentiate into one or more types of mature cells, and generate colonies of 
differentiated cells. There are two major types of stem cells – adult stem cells and 
embryonic stem cells (ESCs). The difference between these two types of stem cells is that 
while adult stem cells have the ability to differentiate into several different types cells, 
embryonic stem cells have the ability to differentiate into any type of cell. Specifically, 
embryonic stem cells have the ability to differentiate into cardiomyocytes with the 
capacity to propagate action potentials, making them a focus in the field of cardiac 
regeneration [96].  Studies have shown that when human ESCs are cultivated in 
suspension they form contracting areas known as embryoid bodies. These embryoid 
bodies contain components such as a heavy myosin chain, α-actinin, desmin, and 
troponin I which indicate cardiomyocyte formation [67].  
 Despite all of these positive attributes, embryonic stem cells are one of the most 
controversial cell types being explored for cardiac regeneration. This is due mostly in part 
to controversy surrounding the ethical questions raised by their use. However, things such 
as the formation of masses of tissue cells known as a teratomas and negative immune 
response have also raised question as to whether the ideal integration of these cells is 
worth the potential risk [8]. 
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Skeletal Myoblasts 
 To eliminate some of the controversy associated with the use of embryonic stem 
cells, research has been focused on finding a cell-based therapy that is derived from adult 
cells. One such type of cells that have undergone significant research is skeletal 
myoblasts. Skeletal myoblasts are acquired via skeletal muscle biopsy. The fact that these 
cells are derived directly from the patient avoids obstacles such as immunosuppression 
and finding a consistent source of cells. Additionally, the risk of teratoma formation is 
minimized due to the fact that these are myogenic cells [8].  
 Despite the fact that studies examining the administration of these cells have 
demonstrated a functional improvement when engrafted post myocardial infarction, the 
skeletal myoblasts have not been proven to differentiate into cardiomyocytes [68, 69]. 
They do, however, secrete various angiogeneic and anti-apoptotic factors that are 
believed to be responsible for the beneficial effects observed in these studies [70]. This 
lack of differentiation is one of the major disadvantages of using skeletal myoblasts for 
cardiac regeneration as this means that they do not form electrical junctions and therefore 
the patient may exhibit tachycardia [68]. 
 
Bone Marrow Derived Mononuclear Cells 
 Bone marrow contains hematopoetic stem cells as well as other stem cells that are 
believed to have the plasticity necessary to form cardiomyocytes. For this reason, studies 
have explored the use of bone marrow mononuclear cells for cardiac regeneration [8]. 
These cells, stimulated by granulocyte colony-stimulating factor (G-CSF) and stem cell 
factor improved ventricular function and regenerated cardiomyocytes [71]. Several other 
studies, however, showed an accelerated recovery but not a continued improvement in the 
ventricular function. Additionally, some studies showed only neutral results. For this 
reason, clinical applications of the bone marrow derived mononuclear cells have received 
much scrutiny [8]. 
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Endothelial Progenitor Cells 
 Endothelial progenitor cells are the precursors to endothelial cells. Studies using 
various methods to deliver endothelial progenitor cells in a rat model of myocardial 
infarction have been executed over the last several years. These studies highlighted the 
fact that different methods of delivery can produce different results. For example, 
neovascularization was exhibited when endothelial progenitor cells were administered 
intravenously. However, when injected locally an increased proliferation of both 
myocytes and vascular structures was observed. The primary mechanism of action of 
these cells is based on neovascularization, which helps to protect the damaged 
cardiomyocytes from apoptosis. This method does not, however, proliferate 
cardiomyocytes, which puts it behind some of the more preferred cell types [8].  
 
Mesenchymal Stem Cells 
 Mesenchymal stem cells (MSCs) were first found in bone marrow. They can also 
be found in umbilical chord blood, adipose tissue and the heart itself. This fact makes it 
one of the easiest cell types to obtain. These non-hematopoetic cells have exhibited the 
ability to differentiate into various types of mesodermal cells [8]. Studies using MSCs in 
both rat and porcine models showed that the introduction of MSCs after myocardial 
infarction reduced infarct size and improved remodeling [72, 73]. Studies suggest that 
because of the reduction in infarct size and improved remodeling, as well as an increase 
in myocardial tissue and left ventricular function, that the MSCs stimulate a repair 
mechanism [8].  
 Unfortunately, the mesenchymal stem cells studied have not shown any evidence 
to suggest that they are able to differentiate into cardiomyocytes. Additionally, these 
studies also show a decline in the presence of the mesenchymal cells over time. This 
leads to the belief that if one could maintain the presence of the mesenchymal stem cells 
in the infarcted area for a longer period of time, there would be even better repair of the 
infarct. It is this belief that has led studies to suggest the use of growth factors or other 
stimuli to improve the length of cell survival [8]. 
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Cardiac Stem Cells 
 When cell-based therapies began to be explored for use in the heart, it was only a 
matter of time before the idea of using a cell-therapy that was derived directly from the 
heart would be explored. Cardiac stem cells are cells that are found in the heart and are 
part of the cardiomyocyte lineage. This indicates the potential ability of these cells to 
differentiate into cardiomyocytes. Additionally, because cardiac stem cells can be grown 
from samples taken from endocardial biopsy, these cells boast the possibility of being 
used for autologous therapy. This would greatly minimize the chance of autoimmune 
response upon injection of the therapy.  Despite the fact that cardiac stem cell therapy has 
been shown to stimulate myocardial and vascular regeneration, there has not been 
substantial evidence that these cells differentiate into cardiomyocytes when introduced 
into the heart post-infarction [8]. 
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Table 2: Summary of Stem Cells Therapies 
Types of Stem Cells PROS CONS 
Embryonic Stem Cells 
(ESC) 
• Can differentiate into 
cardiomyocytes with the 
ability to propagate action 
potentials  
• Can become endothelial and 
smooth muscle cells 
• Teratoma formation 
• Ethical issues 
Skeletal Myoblasts • Derived from autologous cells, 
no need for immune 
suppression 
• Resistant to ischemia 
• Less teratogenic than ESCs 
• Have not been proven 
to differentiate into 
cardiomyocytes 
Bone Marrow Derived 
Mononuclear Cells 
(BMNC) 
• Can improve LV Function 
• Regenerates cardiomyocytes, 
endothelial cells, and smooth 
muscle cells 
• Neutral study results 
add to controversy 
surrounding BMNCs 
Endothelial Progenitor 
Cells (EPC) 
Intracoronary applications showed- 
• Improved LV function 
• Improved myocardial 
perfusion 
• Reduction in infarct size 
• Not a lot of work has 
been done with these 
types of cells in 
comparison  
Mesenchymal Stem Cells 
(MSC) 
Animal studies showed- 
• Improved LV Function  
• Reduction in infarct size 
• Easy to harvest for use 
• MSC retention declines 
over time 
• Not sufficient evidence 
that MSCs differentiate 
into cardiomyocytes 
Cardiac Stem Cells 
(CSC) 
• Exhibit myocardial and 
vascular regeneration 
• Relatively easy to obtain 
• Are derived from patient and 
can be used for autologous 
therapy  
• A lot is unknown about 
CSCs and what the best 
ways to use them are  
• Have not been proven 
to differentiate into 
cardiomyocytes 
 
2.6 Other Therapies for MI Treatment 
The controversy surrounding cell-based therapy has made its integration into the 
medical world a difficult one. Other novel treatments for heart failure are also being 
explored that may be less controversial and equally or more effective. Although these 
therapies do not regenerate the myocardium, they may be able to prevent further 
dilatation and remodeling.   
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2.6.1 Growth Hormone  
Animal studies have shown that growth hormone (GH) may improve myocardial 
function and attenuate LV remodeling following myocardial infarction.  GH treatment 
acts by reducing apoptosis, enhancing angiogenesis, and inducing cardiomyocyte 
hypertrophy, which prevents wall thinning and prevents increases in wall stresses.  
Although studies in animals have shown positive results, human studies have not had 
such positive outcomes [74, 75, 76].  This may be due to the fact that patients simply did 
not respond to GH treatment, sample sizes may have been too low to detect significant 
differences, doses may have been too low, or it may be due to the fact that the treatment 
takes a long period of time before results can be detected [74, 75].  One clinical study 
reported that patients treated with GH reported a feeling of “well being,” although no 
significant changes in LV function were observed [77]. 
The main drawback of growth hormone treatment is that it may prevent LV 
remodeling, but it will not be able to reverse the effects of remodeling [11].  Also, high 
doses of GH administered for treatment may be unsafe because systemic exposure can 
cause hyperglycemia, diabetes, and hypertension [74]. 
2.6.2 Atrial Natriuretic Peptide (ANP) 
 Atrial Natriuretic Peptide (ANP) is produced primarily in the heart’s atria. ANP 
increases venous capacitance and promotes the excretion of sodium, thereby reducing 
extracellular fluid volume. It further reduces peripheral vascular resistance and lowers 
blood pressure. Several hormones and neurotransmitters including endothelin, arginine 
vasopressin, and catecholamines directly stimulate the release of ANP. In the context of 
heart failure, cardiomyocyte hypertrophy leads to elevated ventricular production of ANP 
and increased plasma levels of angiotensin II and endothelin-1 further initiate its release 
into circulation. In NYHA class IV heart failure patients, the concentration of ANP can 
be as high as 30 times the normal level. Animal heart failure studies have demonstrated 
that ANP serves to inhibit the production of molecules such as angiotensin II and 
endothelin-1, inhibit the growth of cardiac fibroblasts and induce cardiomyocyte 
apoptosis. The mechanisms of ANP may serve to attenuate the early hypertrophic 
cardiomyocyte response to an event such as myocardial infarction [78].  
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 ANP release is seemingly a mechanism utilized by the heart to limit remodeling 
following an event such as myocardial infarction. However, high doses of ANP increase 
peripheral vascular resistance even though low doses initially decrease blood pressure 
[78]. In chronic heart failure patients, there is a decrease in the responsiveness of ANP’s 
receptor. Treatment with a LVAD or CSD has been shown to reestablish the sensitivity of 
the ANP receptor and to decrease mRNA expression of ANP to near normal levels [48, 
79]. One study observed that ANP infusion immediately after percutaneous transluminal 
coronary angioplasty (PTCA) can prevent LV dilatation and improve left ventricular 
ejection fraction in patients with a first anterior acute myocardial infarction. The 
suggested mechanism of action included suppression of circulating levels of angiotensin 
II and endothelin-1 [12].  
2.6.3 Granulocyte Colony-Stimulating Factor (G-CSF) 
 G-CSF is one of the most thoroughly studied growth factors in the context of 
myocardial infarction. It has been reported to perform a number of functions including 
the mobilization of hematopoietic precursor cells from the bone marrow and the 
stimulation of endothelial cell migration. Other studies with G-CSF delivery as a therapy 
following MI have shown overall improvements in cardiac function and reduction in LV 
remodeling. Recent clinical trials have also demonstrated that G-CSF is safe and effective 
in improving LV functions in patients post-infarction. However, the employment of G-
CSF as a treatment has not been without negative results. In one study, G-CSF was 
associated with three patient deaths, while in another it was shown to be ineffective at 
improving LV function [80].  
 In an animal study, it was observed that the timing of the start of G-CSF treatment 
was important. The beneficial effects of the treatment were larger when the treatment was 
started as soon after MI as possible. Early clinical safety and feasibility studies reported 
mixed results and the efficacy of G-CSF treatment was inconsistent, especially because 
the inclusion criteria for patients differed markedly from trial to trial. Furthermore, the 
effective dosage, administration rates, and time period to start the treatment have not 
been established [81]. 
 34 
2.6.4 Matrix Metalloproteinase (MMP) Inhibitors 
 Another promising therapy after myocardial infarction is the delivery of matrix 
metalloproteinase (MMP) inhibitors. MMP is an enzyme that has multiple functions, 
most importantly degradation of ECM. MMPs function at neutral pH level can be 
controlled by use of specific tissue inhibitors of metalloproteinases (TIMPs). MMPs 
usually are activated during embryonic development, bone remodeling, and wound 
healing. They destroy the damaged tissue including the ECM, which is eventually 
replaced with scar tissue. The use of MMP inhibitors may prevent further remodeling 
after myocardial infarction. MMP inhibitors are most effective when used immediately 
following myocardial infarction (less than one day) in order to prevent MMPs from 
destroying the ECM [82].  
 It has been shown in many animal studies that MMP inhibitors are able to 
improve heart function by reducing infarct zones and improving ejection fraction. 
However, these positive outcomes have not been shown during human clinical studies 
[83]. Clearly, there is a need for further investigation on MMP inhibitors for the treatment 
of infarcted tissue in humans. 
2.6.5 Vascular Endothelial Growth Factor (VEGF) 
VEGF is a vital promoter of angiogenesis – the process of forming new blood 
vessels from existing vessels through the recruitment of associated supporting cells. The 
rate of angiogenesis is determined by the levels of both angiogenesis inhibitors and 
promoters. After ischemia, hypertrophy increases the heart’s demand for oxygen and 
nutrients. However, hypertrophy causes a reduced number of capillaries to supply a larger 
volume of cardiac tissue and thus coronary flow is greatly impaired. The decrease in 
perfusion results in a reduced supply of nutrients and oxygen, which may be a 
contributing factor to the decline of contractile function [9].  
VEGF stimulates the formation of capillaries by increasing the proliferation and 
migration of endothelial cells, the remodeling of the extracellular matrix, and the 
formation of capillary tubules. VEGF production may be stimulated by interleukin 1-β, 
platelet-derived growth factor (PDGF), and transforming growth factor β. Additionally, 
the absence of VEGF has been linked to a degeneration of vasculature [9, 84].   
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The administration of VEGF either via direct administration or genetic transfer 
using plasmids or adenoviruses is currently being investigated as a therapy post-
infarction. Early VEGF administration post-infarction reduced ventricular enlargement, 
increased capillary density, and reduced the size of the infarcted region [10, 85]. In 
addition, early administration decreased the rate of cardiomyocyte apoptosis in the border 
zone of the infarcted region [85]. In later phases of hypertrophy VEGF administration has 
been shown to aid in the recovery of contractile function, slow the process of ventricular 
dilatation, and reestablish near normal levels of developed pressure [10, 85]. 
2.6.6 Platelet-Derived Growth Factor (PDGF) 
PDGF is an angiogenesis promoter that stimulates the formation of arterioles by 
promoting smooth muscle cell recruitment. PDGF is also partially responsible for the 
maturation of blood vessels because it stimulates smooth muscle cell recruitment to 
newly formed vessels. Early administration of PDGF using an injectable, biodegradable 
hydrogel increased the density of vessels containing smooth muscle cells, but did not 
increase capillary density. Also, ejection fraction was sustained and a smaller degree of 
LV dilatation was noted, demonstrating an improvement in left ventricular function [85, 
86]. 
The use of PDGF and VEGF in combination has also been investigated because it 
is hypothesized that simultaneous treatment with these two proteins will offer the benefits 
of both proteins by stimulating vessel formation and subsequently enhancing vessel 
maturation. Hao et al. have shown that treatment with PDGF and VEGF increased 
capillary density, increased the density of smooth muscle containing vessels, and 
improved left ventricular function [85, 86].  
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3 Project Approach 
 A thorough literature review provided the team with the necessary information to 
begin formulating design solutions to achieve the project objectives. 
3.1 Initial Hypothesis 
 The main objective of this project was to design a left ventricular (LV) restraint 
device that improves LV function through a combination of contractile support and 
delivery of a therapeutic agent. Current post-infarction drug therapies serve mainly to 
prevent further worsening of LV function. Furthermore, many of the researched LV 
restraint devices are passive devices that serve to limit LV enlargement, but they do not 
actively assist in contraction. Some regenerative agents are currently being investigated 
which may hold promise as therapies that can aid in the regeneration of functional 
myocardium. We hypothesized that a LV restraint device can be made of a contractile 
material that can contract 75 beats/min with a contraction duration of 0.3 seconds [21]. In 
addition, we further hypothesized that a regenerative agent can be incorporated into the 
device. 
3.2 Revised Hypothesis 
 The main objective of this project was to design a left ventricular (LV) restraint 
device that improves LV function by providing structural support and delivering a 
therapeutic agent. Current post-infarction drug therapies serve mainly to prevent further 
worsening of LV function. Furthermore, many of the researched LV restraint devices 
serve to limit LV enlargement, but do not serve as a treatment for heart failure. We 
hypothesized that a LV restraint that incorporates growth factors, biomolecules, or stem 
cells and provides structural support can serve as a treatment for heart failure. 
3.3 Assumptions 
 To simplify the scope of the project and provide for its feasibility, the following 
assumptions were made: 
• Appropriate therapeutic agents delivered locally to the infarct can aid in the repair 
of myocardium. 
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• The above-mentioned therapeutic agents will not interfere with the functioning of 
the non-infarcted myocardium. 
• Contractile assistance to the dysfunctional LV will result in beneficial unloading 
of the LV. 
3.4 Specific Aims 
 The specific aims of the project that will achieve the above-mentioned objectives 
were the following: 
• Characterize and test a suitable material to serve as the contractile component of 
the device. 
• Select a suitable therapeutic agent based on the literature that will aid in the repair 
of the myocardium. 
• Perform testing on the biomaterial to ensure that the therapeutic agent has been 
incorporated into the device. 
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4 Design 
At the beginning of the project, the team received the following initial client 
statement: “Design and build a left ventricular restraint device that also serves as a 
therapeutic delivery system for patients suffering from advanced heart failure.” 
In order to further develop this client statement, an engineering design process 
was followed. First, functions, objectives, and constraints were developed for the device 
based on input from both the team and the stakeholders. Based on the identified functions 
and objectives, a revised client statement was developed that clearly reflects the design 
problem being assessed. Next, design specifications were developed to identify 
performance levels for the design and establish specific values for attributes of the 
device. Finally, a list of design alternatives was generated and evaluated to select a final 
design for the device. 
4.1 Stakeholders 
With any design process, there are three main stakeholders involved – the 
designers, the users, and the clients. In the context of this project, the designers were the 
members of the MQP team and the client was the project advisor, Professor Glenn 
Gaudette. The designers and the client had all the input in defining the objectives and 
functions, generating design alternatives, and selecting a final design.  
 The users of the device will be cardiac surgeons. In addition to considering input 
from the client, the needs of the users were considered because if the device did not meet 
the users’ needs, the device would not be marketable.  
4.2 Objectives, Constraints, and Functions 
Based on input from the client as well as a thorough review of the literature, the 
desired and required objectives of the device were identified. The primary desired and 
required objectives with sub-objectives can be seen below, where required objectives are 
shown in bold and desired objectives are italicized: 
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OBJECTIVES (Required, Desired) 
1. Have appropriate physical properties 
i. Have appropriate mechanical properties 
• Have the necessary tensile strength 
• Be fatigue resistant 
• Be wear resistant 
• Have the necessary elastic properties 
ii. Have appropriate contractile properties 
2. Clinically appropriate 
i. Require a simple implantation procedure 
• Be compatible with existing surgical techniques 
• Require a short recovery time for the patient 
3. Marketable 
i. Be minimal cost 
ii. Use available materials 
• Use materials that are easily accessible 
• Use economical materials 
iii. Be easily produced 
 
The first primary objective was for the device to have the appropriate physical 
properties, which included both mechanical properties and contractile properties. Without 
the necessary physical properties, the device will be unable to perform its intended 
functions and may undergo failure upon implantation. It was important for the device to 
have the necessary tensile strength because it must be able to withstand the ventricular 
pressure during systole without failing. Similarly, the device must also be elastic in order 
to withstand the strains that occur during diastolic filling. Fatigue and wear resistance 
were also important since the device will undergo cyclic loading as the heart beats. In 
addition to mechanical properties, if the device is intended to contract, it should have 
contractile properties similar to that of the native heart. Without the appropriate 
contractile properties, the device may induce arrhythmias, which could be fatal for the 
patient. 
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Along with having the appropriate physical properties, the device must also be 
clinically applicable. The device should be designed such that a simple implantation 
procedure is required with a short recovery time for the patient. It was desirable that the 
implantation procedure be compatible with current surgical techniques because this will 
not require cardiac surgeons to learn new surgical techniques or purchase new surgical 
tools, making it more likely that they will use the device. 
The last primary objective was that the device be marketable. In order for it to be 
marketable, it should be of minimal cost and use available materials that are both 
economical and easily accessible. It was desirable that the device be easily produced 
because this will minimize the cost of manufacturing as well as the time it takes to 
manufacture.  
In order to better understand the relative relationships of each objective and sub-
objective, an objective tree was developed. A weighted objective tree was then created 
using only the first and second level objectives to understand the relative importance of 
each objective. In order to define the weight of each objective, a pairwise comparison 
chart was completed by the design team which can be found in Appendix B. The 
weighted objective tree that was developed can be seen below in Figure 6, where the 
number under each objective corresponds to the weight of the objective out of 100%. 
 
 
Figure 6: Weighted Objective Tree 
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In addition to objectives, the following constraints were developed in order to 
limit the design space: 
 
CONSTRAINTS 
1. Must be biocompatible 
i. Must be non-toxic 
ii. Must not induce an inflammatory response 
iii. Must be hemocompatible 
2. Design cost cannot exceed $624 
3. Must be completed by April 2008 
 
It was imperative that the device be biocompatible so that it would not induce an 
undesirable immune or inflammatory response. Since the device may be in contact with 
blood, it should not induce thrombus formation or promote the adherence of proteins on 
the surface. Also, the design must be developed within the team’s budget and time frame.  
Based on the objectives and constraints identified, the team then developed a list 
of functions that the device must perform in order to meet the established requirements. 
The following primary functions were developed: 
 
PRIMARY FUNCTIONS (Required, Desired) 
1. Provide structural/mechanical support to prevent LV remodeling 
2. Provide contractile support to increase cardiac output 
3. Incorporate a therapeutic agent 
 
To improve the function of the infarcted area, the device should provide support to the 
left ventricle to prevent further remodeling. It was desirable that the device provide 
contractile support to the heart during contraction, thus increasing cardiac output and 
unloading the left ventricle. Finally, the device should incorporate a therapeutic agent that 
will aid in regeneration of the myocardium. 
In addition to the list of primary functions described above, the following desired 
and undesired secondary functions were also identified: 
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DESIRED SECONDARY FUNCTIONS 
1. Increase tissue perfusion 
2. Decrease wall stresses 
3. Decrease LV dilatation  
4. Differentiation of cells to cardiomyocytes 
5. Attachment of the device to the heart 
6. Synchronous contraction with the heart 
7. Increase ejection fraction 
 
UNDESIRED SECONDARY FUNCTIONS 
1. Produce degradation products 
2. Obstruction of blood vessels 
3. Induce changes in pH 
4. Induce changes in action potential 
5. Induce arrhythmias 
6. Induce clotting 
7. Induce foreign body response 
8. Systemic delivery of therapeutic treatment 
9. Weakening of existing myocardium 
 
The first desired secondary function was that the device increase tissue perfusion as a 
result of unloading the left ventricle. The device should decrease wall stresses and LV 
dilatation as it prevents further LV remodeling. Should stem cells be incorporated into the 
device as a therapeutic agent, the cells must differentiate into cardiomyocytes. The device 
should be able to be attached directly to the heart. In the case of a contractile restraint, it 
was important that the device contract synchronously with the heart in order to prevent 
arrhythmias. Additionally, as the device provides contractile support to the heart, it 
should subsequently increase ejection fraction.  
Along with the primary functions and desired secondary functions came a set of 
undesired secondary functions. The device should not produce harmful degradation 
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products that can damage the surrounding tissue or can travel through the blood stream 
thereby damaging other tissues. The placement or function of the device cannot obstruct 
the surrounding coronary arteries and other vessels because this will limit blood flow and 
decrease tissue perfusion. Changes in pH should not be induced by the device as this may 
cause changes in the performance of the heart. The device should not induce arrhythmias 
or changes in action potential because this will disrupt the natural contraction of the 
heart. The device should not induce blood clotting or a foreign body response. The 
therapeutic agent incorporated into the device should not be delivered systemically 
because this may interfere with the functions of the body’s vital organs. Finally, the 
device should not cause a weakening of the existing myocardium since this will cause a 
decrease in cardiac output and ejection fraction because this will lead to a decrease in 
global heart function. 
4.3 Revised Client Statement 
 With the objectives, constraints, and functions of the device defined, the 
following revised client statement was developed that clearly reflects the design problem: 
 
“Myocardial infarction can lead to LV remodeling characterized by dilatation and 
wall thinning which can cause end-stage heart failure and eventually death.  Despite the 
fact that there have been advances made in the treatment of heart failure, there are 
currently no devices on the market that simultaneously reverse the effects of LV 
remodeling and regenerate myocardium.  Design, build, and test a device that will 
improve the function of the infarcted area by providing structural support to the failing 
heart while also incorporating a therapeutic agent.  It is also desirable that the device 
provide contractile assistance to the heart to aid in the recovery of global heart function. 
The device would be intended for patients with late stage III and early stage IV heart 
failure.”   
4.4 Design Specifications 
Once the objectives and functions of the device were identified, a set of design 
specifications was developed to identify performance levels for the design. The design 
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specifications for the device are listed below in Table 3 and calculations are further 
explained in Appendices C-D. 
 
Table 3: Design Specifications 
Design Specification Description 
Wall tension The device must be able to withstand a wall tension of 
1.37 N/mm [87] 
Strain The device must be able to withstand a strain of 15-
20% [88] 
Fatigue The device must have a wall tension and strain that is 
not statistically significant after 1,000 cycles [87, 89] 
Contraction rate 
(if applicable) 
The device should be able to contract 75 times/min 
[21] 
Contraction duration 
(if applicable) 
The duration of contraction should not be more than 
0.3 sec [21] 
 
To ensure that the device has the appropriate mechanical properties, it should be 
able to withstand the specified wall tension, strain, and fatigue strength. The calculated 
wall tension was based on the wall stress of patients with high ventricular pressure and 
incorporated a safety factor of 5. The wall tension is a normalized function of wall stress 
because it is divided by the thickness of the wall. Since the device would be intended for 
patients with class III or IV heart failure, it should withstand cyclic loading for a 
minimum of 2 years, which corresponds to 78,840,000 cycles based on an average heart 
beat of 75 beats/min [21, 87, 89]. Since this number of cycles was not reasonable to test, 
the wall tension and strain after 1,000 cycles should be tested. 
In addition to mechanical properties, a contractile device must also have the 
appropriate contractile properties to ensure that it does not induce arrhythmias. If the 
device was designed to contract, it should contract at a rate equivalent to a normal heart 
rate, which is 75 beats/min, and the contraction duration should be equivalent to the 
duration of ventricular contraction, which is 0.3 sec [21]. 
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4.5 Developing Design Alternatives 
In order to begin identifying potential designs, a morphological chart, which can 
be found in Table 4, was created to effectively visualize the size of the design space.  
 
Table 4: Morphological Chart 
FUNCTIONS MEANS 
Provide 
structural/mechanical 
support 
Cardiac 
patch 
Wrap 
restraint 
Nut & bolt 
restraint 
Band 
Incorporate a 
therapeutic agent 
Cells Drugs Growth 
factors 
Proteins 
Provide contractile 
support (desired) 
Contractile 
biomaterial 
LVAD ----- ----- 
 
Subsequently, a functions-means tree was created to graphically represent the means 
identified for each function in the morphological chart. The functions-means tree can be 
seen in Figure 7 on the next page. 
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The means identified for each function were combined to create a number of different 
design alternatives. For example, the following design alternatives were generated: 
1. Cardiac patch, contractile biomaterial, cells 
2. Cardiac patch, contractile biomaterial, growth factors 
3. Wrap restraint, contractile biomaterial, drugs 
4. Band restraint, contractile biomaterial, growth factors 
5. Nut & bolt restraint, contractile biomaterial, proteins 
6. Nut & bolt restraint, LVAD, proteins 
The design alternatives that were generated can be found in Appendix E. 
4.6 Evaluating Design Alternatives 
The design alternatives developed in the previous section were evaluated using an 
evaluation matrix. The designs were evaluated based on the constraints to ensure that the 
design met the specified constraint. The design alternatives were evaluated to determine 
how well each design satisfied the established objectives. The designs were rated on a 
scale of 0 to 5, where 0 indicated that the design would not meet the objective at all and 5 
indicated the design would completely meet the objective. The weight of each objective 
was obtained from the pairwise comparison chart found in Appendix B. To determine the 
total score of each design, the weight for each objective was multiplied by the score for 
the objective, then each rating was added to obtain the combined total. The evaluation 
matrix can be found in Appendix F along with an explanation of the basis for comparison 
that was used and the scores assigned to each design. The total score for each design can 
be seen in Table 5 below.  
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Table 5: Evaluation of Design Alternatives 
Design Total score 
Contractile biomaterial, wrap 
restraint, and cells or growth 
factors 
2.803 
Contractile biomaterial, nut & 
bolt restraint, and cells or 
growth factors on end caps 
2.979 
Contractile biomaterial, hoops 
or strips, cells or growth 
factors 
2.479 
Contractile biomaterial, patch, 
cells or growth factors 
2.717 
Passive wrap restraint with 
cells or growth factors  
2.575 
Passive band restraint with 
cells or growth factors 
2.432 
Passive patch with cells or 
growth factors 
2.099 
 
The design alternative with the highest score was the nut and bolt restraint using a 
contractile biomaterial with cells or growth factors on the end caps. The major advantage 
of this design was that the propagation of the contraction would not need to be precisely 
controlled because the contractile biomaterial would not be wrapped around a large area 
of the heart. This design could also be manufactured more easily due to its relatively 
simple design, in comparison to the wrap restraint, which would be more difficult to 
manufacture. Additionally, the delivery of cells or growth factors could be localized to 
the infarct by placing them only on the end pads of the device. This design alternative 
also has some disadvantages including the difficulty of implantation as the device must 
penetrate the ventricular wall and the limited mechanical support. 
4.7 Final Design with Polyaniline 
With the nut and bolt restraint design, the device consisted of two parts – the 
splint and the end pads. Polyaniline (PANI) was chosen for the contractile biomaterial 
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component because it was the most extensively researched contractile biomaterial and the 
most promising for biological applications. Studies have demonstrated that PANI can be 
biocompatible and potentially biodegradable. Also, the properties of PANI including the 
electrical conductivity and stability can be controlled by altering the manufacturing 
processes used. PANI can be used for the splint as well as the end caps, if it is able to 
sufficiently hold growth factors and/or cells. If the entire device was made of PANI, this 
would minimize any stress concentrations and mismatch of mechanical properties at the 
interface between the splint and end pads. However, if PANI is unable to hold growth 
factors or cells, other materials such as collagen sponges, PEUU, ECM, and fibrin glue, 
which can hold and deliver the therapeutic agent, could possibly be used for the end pads.  
A detailed drawing of the device can be seen below in Figure 8. The splint would 
penetrate through the myocardium without passing through the septum. The epicardial 
pads would be located on the epicardium and would attach to the ends of the splint. The 
contractile biomaterial could be stimulated by a stimulus unit, such as a pacemaker, 
which would ensure that the device contracted simultaneously with the native heart to 
prevent arrhythmias.  
 
Figure 8: Final Design with Polyaniline 
4.8 Re-evaluating Design Alternatives 
As described in the Results section (Sections 6.1 and 6.2), PANI proved to be 
very difficult to manufacture and could not be electrically stimulated. It was unlikely that 
PANI would meet the design objectives, specifically because it could not be easily 
produced and would likely not have the appropriate mechanical or contractile properties. 
Thus, the designs were re-evaluated to select a design that did not incorporate a 
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contractile biomaterial. From Appendix F the design alternative that scored the highest 
and did not incorporate a contractile biomaterial was the passive wrap restraint that 
incorporated cells or growth factors. The major advantage of this design was that it can 
provide the largest degree of mechanical support because it would enclose the entire 
heart, preventing hypertrophy in all areas. Also, it would require a relatively simple 
implantation procedure because it would be able to be secured by wrapping it around the 
heart. The major disadvantage of the design was that it may be difficult to produce due to 
the intricacies of the complex mesh design. Also, it was not as cost efficient as other 
designs because it required the use of more material. 
4.9  Final Design with Microthreads 
For the final design, souble collagen microthreads were selected as the major 
component of the device. As described in Section 2.4.3, collagen microthreads offer the 
advantage of high mechanical strength and can be manufactured to hold proteins, growth 
factors, or cells. Collagen microthreads are biocompatible and have been investigated 
extensively for use in repair and regeneration of ligaments and tendons [19]. In addition a 
therapeutic agent was incorporated into the microthreads to promote angiogenesis around 
the infarcted region. Platelet-derived growth factor (PDGF) was selected due to its 
availability because the group was unable to purchase other growth factors, proteins, or 
cells due to budget constraints. 
A detailed drawing of the final design can be seen in Figure 9. In order to ensure 
that the device is as cost effective as possible, PDGF could only be incorporated into the 
microthreads placed over the infarcted region. The surgeon would be able to position the 
wrap such that the area with PDGF is placed over the desired region. Additionally, local 
delivery of growth factors would prevent any adverse consequences that may occur in 
other areas of the heart. 
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Figure 9: Final Design with Microthreads 
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5 Methodology 
This section describes the methodology used to manufacture and test PANI and 
collagen microthreads. These methods were used to determine and test a suitable material 
for use in a LV restraint device. 
5.1 Cell Culture 
 Human mesenchymal stem cells (HMSCs) and rat aortic smooth muscle cells 
(SMCs) were grown using cell culture techniques. Biocompatibility testing of polyaniline 
was planned using HMSCs and cell migration assays on microthreads were performed 
using SMCs. HMSCs were between passages 9 and 14. SMCs were obtained from 
Professor Rolle’s lab and the passages were unknown. Both types of cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS). 
The cells were stored in T-75 culture flasks in a 37°C, 5% CO2 incubator.  The cell media 
was replaced every 3 to 4 days for HMSCs and every 2 days for SMCs. 
When splitting cells due to over confluence 0.25% trypsin was used to detach 
cells. In order to trypsinize the cells the media was first aspirated. A rinse of 10mL 
Hank’s Balance or DMEM solution was used to wash the flask. Afterwards, 1mL of 
0.25% trypsin was added and the flask was put under a microscope. The cells were then 
watched until they were visibly detached from the bottom of the flask (approximately 2-3 
minutes for HMSCs and approximately 7 minutes for SMCs). 10mL of media was then 
added and pipetted into a 20mL centrifuge tube. The cells were then spun down at 
600RPMs for 3 minutes. The media was aspirated off and fresh media was added while 
agitating the cells. The desired amount of cells was then put into T-75 culture flasks and 
additional media was added to a total volume of 10mL.   
5.2 Manufacturing Polyaniline Films 
PANI films were produced by solvent casting solutions of PANI dissolved in 
NMP onto glass surfaces. Protocols for producing PANI films were developed based on 
literature and information gathered by material science specialists, the best of which was 
determined through trial and error. Detailed protocols for all methods used to produce 
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PANI films can be found in Appendix H, including the methods used to produce optimal 
films.  
To produce optimal films, 4% wt/vol of PANI was mixed in NMP solvent 
overnight. The solution was then cast on to glass tissue culture discs or glass slides by 
placing 35µL on each disc or 300µL on each slide. The solutions must be cast onto a 
glass surface because NMP, which is an organic solvent, will dissolve plastic surfaces. In 
order to ensure that the NMP solvent diffused uniformly out of the solution, the slides 
and/or discs were placed in a vacuum chamber overnight with a light vacuum applied. 
The chamber was cracked open slightly to allow airflow to circulate throughout, as 
shown in Figure 10 below, where the red arrow points to a slide of PANI solution. When 
the films were dry, they were washed in phosphate buffer solution (PBS) three times for 5 
minutes and doped in 1M HCl for 15 minutes. 
 
Figure 10: Set Up for Manufacturing PANI Films 
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5.3 Preliminary Testing of Contractile Properties of Polyaniline 
Once electroactive PANI films were produced, preliminary testing was conducted 
to determine their contractile properties, as detailed in Appendix I. The experimental 
setup for field stimulation is shown in Figure 11, where a PANI strip (about 1 mm wide 
by 1 cm long) was placed in PBS solution in line with the wires as shown in Figure 12.  
Three PANI strips were tested. Using field stimulation, a single pulse was applied 
at 1V and the voltage was increased in increments of 0.5V until the voltage reached 10V. 
As described in Section 6.2, no visual contraction was observed. Point stimulation of 
PANI strips was also tested, where the electrodes were directly connected to each end of 
the PANI strip. Although further testing of PANI was not performed, Appendix I 
contains protocols for testing the contraction length, contraction duration, and contraction 
force. 
 
Figure 11: Contractile Testing Set Up 
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Figure 12: Close-up of PANI Strip During Contractile Testing 
5.4 Manufacturing Microthreads 
Soluble type I collagen fibers were obtained from rat tails and were processed to 
produce a collagen solution. Prior to extrusion, the collagen solution was dissolved in a 
rotating vessel in 5mM HCl at 4˚C at a final concentration of 10mg/mL. The solution was 
then spun in a centrifuge to remove any air bubbles [19]. 
The water bath was set to 37°C and a glass tray filled with 500mL of fiber 
formation buffer (FFB) was placed into the water bath. A syringe was used to take up 
3mL of the collagen solution and polyethylene (PE) tubing with an inner diameter of 0.86 
mm was attached to the syringe. The extrusion pump was then set to extrude the collagen 
at a rate of 0.3mL/min. The syringe was connected to the pump, the pump was turned on, 
and the collagen was carefully watched as it passed through the tubing, as shown in 
Figure 13.  
 
 
electrodes 
electrical tape 
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Figure 13: Set Up for Manufacturing Microthreads 
 
When the collagen came through the end of the tubing, the tubing was slowly dragged 
along the bottom of the glass tray. After the desired number of microthreads was 
extruded, saran wrap was placed over the glass tray and the microthreads were left in 
FFB for 24 hours. After 24 hours, the threads were moved to a bath of fiber incubation 
buffer (FIB) for 24 hours. Afterwards, the microthreads were taken out of the FIB bath 
and hung on a cardboard box using forceps to dry overnight. Multiple soluble collagen 
microthreads were obtained that were about 20cm in length and about 50µm in diameter 
[19].      
5.5 Mechanical Properties of Microthread Mesh 
The microthread mesh will be placed over the heart wall to provide structural 
support. As a result, a composite material is created which consists of the heart wall and 
the microthread mesh. In order to provide structural support, the resulting composite 
material should have a higher stiffness than the native heart wall. Mechanics equations 
for composite materials were used to determine the number of microthreads that would 
be required for the stiffness of the composite to be 10% greater than the stiffness of a 
hypertrophied right ventricular heart wall. The stiffness of the composite material was 
taken to be 10% greater than the native heart wall because it is expected that a small 
increase in stiffness would provide structural support to prevent dilatation, but at the 
same time would not interfere greatly with the contraction of the healthy myocardium. A 
mechanics of materials approach was used with the assumption that the microthreads and 
the heart wall undergo the same strain [90]. This approach is referred to as a constant 
strain model and can be viewed as a model with two springs in parallel, as seen in Figure 
14. 
Syringe with soluble collagen 
PE Tubing 
 
 
  
 
 
  
Glass tray with FBB 
 
Microthread 
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Figure 14: Mechanical Model of Microthreads-Heart Wall Composite 
 
In order to determine the number of microthreads required to increase the stiffness 
of the composite material the rule of mixtures for composite materials was applied. The 
rule of mixtures equation relates each individual material’s contribution to the total 
composite stiffness:  
K+++= 332211C VEVEVEE  
In this equation, EC is the stiffness of the composite material, Ketc ,V ,V ,V 321  are the 
volume fractions of each material, and Ketc ,E ,E ,E 321  are the stiffnesses of each 
material. Each material’s contribution to the composite stiffness is dependent upon the 
stiffness of the material and the fraction of the composite volume that the material 
occupies [90]. 
The following assumptions were made to simplify the calculations: 
• The heart is a hollow sphere 
• All microthreads have the same properties (length, cross-sectional area, 
and stiffness) 
• The stiffness of the right and left ventricles is the same 
Composite loaded in 1 direction: 
HEART WALL 
MICROTHREADS 
σ1 σ1 
L ∆L 
Equivalent to springs in parallel model: 
Heart Wall 
Microthreads σ1 σ1 
k1 
k2 
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• The heart wall is linear elastic 
• The stiffness of the heart wall is constant in the direction of the fibers and 
is constant in the direction perpendicular to the fibers.  
• Fibers in the heart wall run vertically from apex to base 
By using the rule of mixtures constant strain model equation, the number of 
microthreads required to increase the composite stiffness by 10% was calculated. 
Detailed calculations can be found in Appendix K.  
Once the number of microthreads was calculated, basic mechanics equations were 
used to determine if the structural support provided by the mesh would decrease the 
dilatation of the heart wall. The following formula was used to calculate the strain, or 
dilatation, of the heart wall:  
AE
tT
×
×
=ε  
In this formula, ε = strain, T = wall tension, t = wall thickness, E = stiffness, and 
A = cross-sectional area. In order for the mesh restraint to decrease the dilatation of the 
heart wall, the stiffness multiplied by the area of the heart wall-microthread composite 
(product of EA) should be higher than that of the heart wall alone. This quantity was 
calculated for both the composite and heart wall alone in the fiber and cross fiber 
directions. Detailed calculations can be found in Appendix K.  
5.6 Cell Migration Assay 
A cell migration assay was developed in order to determine whether platelet-
derived growth factor (PDGF) would affect the migration rate of cells to the microthread. 
As described in Section 2.6.6, PDGF promotes smooth muscle cell (SMC) recruitment to 
newly formed blood vessels, which is an important part of angiogenesis [9, 86]. 
Therefore the migration rate of SMCs should be greater with microthreads coated in 
PDGF. 
Polydimethylsiloxane (PDMS) was used as a blocker between the microthread 
and SMCs. SMCs were plated on half of the petri dish and the microthread was placed on 
the other side with the PDMS block in between. Once the cells had plated, the PDMS 
block was removed and the cells were allowed to migrate to the other half of the petri 
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dish. The migration and proliferation of SMCs was observed with PDGF coated 
microthreads and control samples (microthreads not coated with PDGF and petri dishes 
without microthreads). The setup for the cell migration assay can be seen in Figure 15. 
 
 
Figure 15: Set Up for Cell Migration Assay 
 
Liquid polydimethylsiloxane (PDMS) was made by mixing silicone elastomer and 
PDMS curing agent in a 10:1 ratio and pouring it into tissue culture plates. The PDMS 
filled plates were placed in a vacuum chamber to remove air bubbles that may have 
formed and was then placed in an oven set to 50˚C for approximately 2 hours. Upon 
hardening, the PDMS was removed from the petri dish. The samples were cut in half with 
a scalpel. Subsequently the ends of the half circles were removed to allow for placement 
of the microthreads on the other end of the petri dish. The PDMS blocks were then 
sterilized in an autoclave.  
All microthreads were sterilized in 70% ethanol for 24 hours and were then 
washed in PBS three times for 5 minutes per wash. PDGF coated microthreads were 
placed in a PDGF solution (10ng/mL PDGF-ββ in DMEM +20%FBS + 1% pen/strep) for 
24 hours and subsequently washed in PBS three times for 5 minutes per wash. The 
microthreads were attached to one side of the petri dish (diameter = 100mm) using sterile 
silicone glue.  
Under the sterile hood, the sterile PDMS blocks were placed in the petri dishes. 
Rat aortic smooth muscle cells (SMCs) were trypsinized and counted using a 
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hemocytometer. SMCs were cultured on the side of the plate opposite the microthread, 
with 50,000 cells cultured on each plate. The cells were allowed to plate down for 24 
hours and the media was aspirated to remove any floating cells. The PDMS block was 
removed and new media was added to the dish.  The plates were visualized and 
photographed at regular intervals under an inverted light microscope to observe the 
differences in migration and proliferation of cells for each sample. Grid lines were drawn 
on the petri dish cover as shown in Figure 16. Pictures were taken at the intersections of 
the grid lines to produce a total of 21 pictures per dish. The pictures were then stitched 
together using Adobe Photoshop CS2.  
 
Figure 16: Cell Migration Assay Photograph Grid Lines 
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6 Results 
This section describes the results obtained from the procedures in the 
Methodology section. 
6.1 Manufacturing Polyaniline Films 
The initial protocol for producing PANI films (obtained from Dr. Gouma’s 
laboratory at Stony Brook University, found in Appendix A) involved making a solution 
of 12% wt/vol PANI in NMP and then casting this solution onto glass slides. The 
resulting films were cracked in certain places, while other areas were very thin and stuck 
to the slides, as seen in Figure 17 below. The slivers of PANI could easily be removed 
from the slide simply by tipping the slide, allowing the pieces of fall off. This type of 
film was not desirable because it was not a continuous, uniform film. 
 
Figure 17: 12% wt/vol PANI Film That is Highly Cracked 
 
After reviewing the literature, a solution of 4% wt/vol of PANI in NMP was made 
and compared to the films obtained using a 12 % wt/vol solution [91, 92]. Furthermore, 
the films were cast on glass tissue culture discs with 35 µL of solution on each disc. The 
slides obtained using a 4% wt/vol solution of PANI were more continuous, more 
uniform, and were not cracked as seen in Figure 18. However these PANI films were 
very thin and could not be removed from the slide. 
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Figure 18: Slide Obtained Using 12% wt/vol Solution of PANI (top) and Slide Obtained Using 4% 
wt/vol Solution of PANI (bottom) 
  
After many iterations it was determined that placing 300 µL on each glass slide 
produced the most uniform and minimally cracked film. A vacuum chamber was used as 
a means of obtaining a more uniform film because it allowed for more even diffusion of 
NMP. Overall, the films dried in the vacuum chamber were more uniform and less 
cracked than those that dried in the fume hood.  
The uniform PANI films that were obtained on the discs and slides were initially 
doped in 1 M HCl for 15 minutes. Within 1 minute of doping, the films were observed to 
crack, split, and fall off the slide as shown in Figure 19. The top slide in Figure 19 is from 
the same batch of PANI solution but was not doped in HCl. However, when slivers of 
PANI were doped (obtained from batches of cracked PANI films when solvent casting 
12% wt/vol solutions), the slivers were able to withstand the doping process. 
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Figure 19: PANI Film Exposed to HCl (bottom) Compared to Control (top) 
 
In addition to doping in HCl, PANI coated tissue culture discs were washed in 
PBS to see if the films would crack when exposed to PBS. The discs were found to crack 
upon washing in PBS and with additional washes in PBS, the amount of cracking 
increased. Three glass discs of 4 % wt/vol PANI that were washed in PBS for 5 minutes 
are shown in Figure 20. The disc in well 1 was not washed in PBS, the disc in well 3 was 
washed once in PBS, and the disc in well 2 was washed twice in PBS.  
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Figure 20: PANI Films Exposed to PBS Washes. (Disc 1 was not washed, disc 3 was exposed to one 
wash in PBS, and disc 2 was exposed to two washes.) 
  
In order to potentially prevent the cracking that was observed when doping the 
PANI films, a higher molecular weight polymer was used (65 kD, in comparison to 
10kD) to make 4 % wt/vol PANI solutions. Upon mixing the PANI in NMP, it was 
observed that the PANI did not dissolve completely in the solvent. Subsequently, the 
dissolved portion of the solution was pipetted off and used to cast PANI films. However, 
the first and only batch of high molecular weight PANI did not form well. As can be seen 
in Figure 21, both PANI films have surface irregularities and roughness in comparison to 
the more uniform films of the lower molecular weight (10kD) PANI. 
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Figure 21: PANI Films of High Molecular Weight Polymer 
 
6.2 Preliminary Testing of Contractile Properties of Polyaniline 
 No visible contraction was observed in any of the three PANI strips that were 
tested. Neither field nor point stimulation produced any macroscopic contraction of the 
doped slivers from a voltage range of 0 to 10 V.  
6.3 Mechanical Properties of Microthread Mesh 
To create a composite material with a stiffness 10% greater than the heart wall, 
the number of microthreads was determined in both the fiber and cross fiber directions 
using the rule of mixtures calculations described in Section 5.5. In the direction of the 
fibers, the number of microthreads required was found to be 21.8 and in the cross fiber 
direction, the number of microthreads required was found to be 11.5. 
In Section 5.5, basic mechanics equations were used to show that the microthread 
mesh can prevent dilatation of the heart. As the product of the elastic modulus and cross-
sectional area (EA) increased, the dilatation of the heart wall would be reduced. In the 
fiber direction, the product of EA for the heart wall was 495.1 N and with the mesh 
restraint, the product was 544.6 N. In the cross fiber direction, the product of EA for the 
heart wall was 137.5 N and with the mesh restraint, the product was 151.3 N. Since the 
product of EA increased with the addition of the mesh restraint, the basic mechanics 
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equation indicated that the mesh would reduce the dilatation of the heart wall. The results 
for these calculations are summarized in Table 6 below.  
 
Table 6: Summary of Calculations of Mechanical Properties 
 Number of 
microthreads 
EA product for 
heart wall [N] 
EA for heart wall with 
mesh restraint [N] 
Fiber direction 21.8 495.1 544.6 
Cross fiber 
direction 
11.5 137.5 151.3 
 
6.4 Cell Migration Assay 
As described in Section 5.6, a cell migration assay was performed to observe the 
migration and proliferation of smooth muscle cells (SMCs) with PDGF coated 
microthreads, control microthreads, and control petri dishes without microthreads. SMCs 
were cultured on one side of the petri dish and the microthread was attached to the other 
side, with a PDMS block separating the two sides. After allowing the cells to plate for 24 
hours, the PDMS block was removed. The experiment was repeated three times to verify 
the reproducibility of the results. 
On the first trial, the cells were not counted properly prior to plating the cells on 
the dish. Seven days after being plated, SMCs were found surrounding the PDGF coated 
microthread, as seen in Figure 22. Cells were seen directly next to the microthread, with a 
few cells branching out toward the microthread. With the control microthread, very few 
cells were seen near the microthread. With the control petri dish (no microthread), a few 
cells were scattered around the black marker, where the microthread would have been. 
Overall, there were many more cells surrounding the PDGF coated microthread in 
comparison to the control samples. Eight days after being plated, sheets of cells began 
lifting off the petri dish and folding over because the cells had overgrown the dish. At 
this point, further testing could not be performed with these samples. 
 
 67 
         
   (a)      (b)  
 
(c) 
Figure 22: Microthreads Seven Days After Plating Taken at 200X Magnification (a) PDGF 
Microthread – Note many smooth muscle cells (SMCs) near microthread (b) Control Microthread – 
Note no SMCs near microtread (c) Control Dish with No Microthread – Note some SMCs near 
marker line 
 
In the second trial, 50,000 SMCs were plated per dish. Three days after being 
plated, cells were observed around the PDGF coated microthread. However, four days 
after being plated, the cells had overgrown the dish. This trial was discontinued because 
many of the cells were aspirated from the dish when the media was changed.   
 In the third trial, two samples were used per group and were labeled as A and B. 
A smaller number of cells were plated on each petri dish (4,700 cells per dish) due to the 
low number of viable SMCs that were available. After being plated, the PDMS block was 
removed after 48 hours, allowing the cells to proliferate in order to increase the cell count 
on each dish. Grid lines were marked on each dish and 21 pictures were taken each day 
for all dishes, as described in Appendix L. The 21 pictures were then stitched together 
using Adobe Photoshop CS2. A characteristic picture of the dishes at the initial time 
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point can be seen in Figure 23, where the halfway point marks where the PDMS block 
was located. 
 
Figure 23: Stitched Picture of Petri Dish at Initial Time Point (Control thread A). 21 individual 
pictures from various points on the petri dish were stitched together using Adobe Photoshop CS2. 
 
Seven days after plating, SMCs were observed surrounding the PDGF coated 
microthread A. However, PDGF coated microthread B had very few cells surrounding it 
in comparison to PDGF coated microthread A and the control dishes without 
microthreads. The control microthread dishes had very few cells surrounding the 
microthreads, while the control dishes without microthreads had some cells scattered 
around the black marker where the microthread would have been. These results can be 
seen in Figure 24 below.  
 
Halfway 
point Thread 
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Figure 24: Microthreads Seven Days After Plating (a) Control Dish with No Microthread (b) Control 
Microthread (c) PDGF Coated Microthread. Individual pictures from various points on the petri 
dish were stitched together using Adobe Photoshop CS2. 
 
Although cells were found surrounding PDGF coated microthread A, the cells did not 
migrate significantly past the halfway point, as seen in Figure 25. Similar to previous 
trials, after eight days the cells overgrew the dish and began folding over, preventing any 
further testing.  
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Figure 25: PDGF Coated Microthread A Seven Days After Plating. 21 individual pictures from 
various points on the petri dish were stitched together using Adobe Photoshop CS2. Note smooth 
muscle cells (SMCs) can be seen around the microthread, however there are not many cells past the 
halfway point. 
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7 Discussion 
This section serves to interpret the results of the polyaniline and microthread 
mesh testing. 
7.1 Polyaniline 
The team had great difficulty producing uniform films of polyaniline. The films 
obtained using the initial protocol from Dr. Gouma’s laboratory were very cracked. 
Initially, it was suspected that the air currents in the fume hood caused the films to crack 
as they dried. Therefore, the procedure described in Appendix H (revised 01/21/08) was 
used to prevent air currents from disrupting the drying film. This procedure involved 
placing the slides or tissue culture discs in covered Petri dishes that had holes cut in the 
top to allow diffusion of NMP. However, the revised procedure resulted in films that 
were just as cracked as previous films and took longer to dry. 
After reviewing the literature, 4% wt/vol PANI solutions were used, rather than 
12% wt/vol solutions [91, 92]. The PANI films produced were much less cracked and 
more uniform than the previously made films. However, the films made using 4% wt/vol 
solutions of PANI were stuck to the disc and could not be removed without destroying 
them. 
It is believed that the cracking of PANI films that was observed during drying was 
due to the poor vaporization characteristics of NMP. NMP has a higher boiling point than 
other solvents such as N-dimethylformamide (DMF) and tetrahydrofuran (THF) and thus 
has inferior vaporization characteristics. The non-uniform diffusion of NMP from the 
PANI solution likely created regions of localized stresses. As the NMP diffused at a 
faster rate in certain areas of the film, this caused the film to be pulled in certain 
directions, resulting in localized fractures during drying. The films made using a higher 
concentration of PANI were more cracked because the higher concentration of polymer 
further impeded the diffusion of NMP. 
In order to prevent the cracking of PANI films, an oven and/or vacuum may be 
used to improve the uniformity of the diffusion of NMP [91]. Using the vacuum chamber, 
 72 
as described in Section 6.1, relatively uniform, un-cracked films of PANI were produced 
on both slides and tissue culture discs. 
Upon producing uniform PANI films, the films were doped in 1M HCl for 15 
minutes to make them electroactive [91]. However, the doping process caused the films 
to crack and split almost immediately. When slivers of PANI were doped (obtained from 
batches of cracked PANI films when solvent casting 12% wt/vol solutions), the slivers 
were able to withstand the doping process. The explanation for the difference observed 
between the PANI films on the slides and discs and the PANI slivers likely stems from 
the residual stresses present in the films. The films that were not able to withstand the 
doping process were attached to the glass surfaces, forcing them to remain in a flat state, 
which is not the natural state of most polymers. The films likely cracked because the 
chloride ions in the HCl attacked the bonds within the PANI, which caused the film to 
unfold into various conformations dictated by the residual stresses that were present. 
These films were also unable to withstand washing in PBS. 
A higher molecular weight polymer (65kD) was used to potentially prevent 
cracking of the film during doping. When mixing a 4% wt/vol solution of PANI, the 
polymer powder did not completely dissolve into solution. Despite minimizing the 
amount of un-dissolved powder that was cast onto the glass slides, the films produced 
were rough and contained surface irregularities. In order to ensure that the solution is 
homogenous and completely dissolved, it can be passed through a filter to remove any 
un-dissolved polymer powder [91]. 
The doped slivers of PANI that were produced using solutions of 12% wt/vol 
were tested to determine their contractile properties. The PANI slivers were tested under 
field and point stimulation with voltages ranging from 0V to 10V. However, no visible 
contraction was observed in any of the samples. There are numerous factors that may 
explain the inability to produce a visible contraction of the PANI slivers. The electric 
stimulation may have been inadequate. For the field stimulation setup, the electric field 
between the wires may not have been directly in line with the PANI strip, thus decreasing 
the amount of current being applied. Furthermore, the resistance of the PBS solution was 
measured with a digital multimeter and found to be on the order of 106 Ohms. Since the 
resistance of the solution was so high, the amount of current that actually reached the 
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PANI may not have been large enough to cause a contraction. With point stimulation, it 
was difficult to maintain contact between the tips of the wires and the ends of the PANI 
strip because the PANI was so brittle and prone to cracking. Additionally, contraction of 
PANI films may have been microscopic and may require more sophisticated equipment 
to visualize. 
In conclusion, processing of polyaniline was very difficult. Uniform films could 
be produced, but could not be easily handled due to their brittle nature. Also, processing 
these films proved problematic because the films could not be easily doped or washed in 
PBS. When contractile testing was performed on slivers of PANI, no visual contraction 
could be observed. Although research has shown that PANI can be electrically 
stimulated, the team’s field research has only confirmed PANI’s ability to be chemically 
stimulated (see Appendix A). The possible microscopic contraction from an electrical 
stimulus or chemical stimulation is not practical for this left ventricular restraint device.  
7.2 Biocompatibility of Microthreads 
The biocompatibility of the microthreads in the device is an important design 
constraint. The acid-soluble type I collagen threads used were made from rat tail tendon. 
Although it was not feasible to test the biocompatibility of the microthreads with cardiac 
cells or human mesenchymal stem cells due to time constraints, the biocompatibility with 
other cell types has been confirmed by previous research. 
Cornwell tested the migration of transduced human dermal fibroblasts along the 
length of collagen microthreads [19]. Cornwell reported that acid-soluble type I collagen 
threads had fibroblast migration rates similar to native threads from rat tail tendons. 
Cornwell cited the work of Koob et al. to further confirm the biocompatibility of collagen 
microthreads. Koob et al. tested the attachment of bovine tendon fibroblasts to type I 
collagen microthreads produced with a crosslinking agent [93, 94]. Koob et al. found that 
about 86% of fibroblasts attached to culture dishes coated in collagen microthreads 
compared to 100% of fibroblasts attached to the polystyrene tissue culture dish control. 
The tendon fibroblast proliferation rates on the collagen microthreads were reported to be 
about half of the fibroblast proliferation rate on the polystyrene tissue culture dish. 
Additionally, no difference in fibroblast morphology between cells on the microthreads 
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or on the dish was reported [93, 94]. Since this research indicates that microthreads are 
viable for use in cell delivery, regenerative agents, such as stem cells, could also be 
incorporated into the device to aid in the regeneration of the myocardium [19]. 
7.3 Mechanical Properties of Microthread Mesh 
The calculations in Section 5.5 and their results in Section 6.3 are simple 
approximations for a LV restraint device made of microthreads. Several assumptions 
about the heart and the microthreads were made to simplify the analysis. It was assumed 
that the dilated heart is a hollow sphere and that the fibers in the left ventricle are oriented 
vertically. The fibers are actually oriented at slight angles from the vertical axis [95]. The 
assumption that the fibers are oriented vertically was made to allow the values for the 
heart wall stiffnesses to correspond to the vertical and horizontal axes in the fiber and 
cross fiber directions, respectively. It was assumed that the values reported for the 
stiffness of hearts with right ventricular hypertrophy could be used in the case of left 
ventricular hypertrophy [95]. It was also assumed that the heart wall tissue is linearly 
elastic, which is not entirely valid because most biological tissues are viscoelastic. 
In addition to the assumptions made about the properties of the heart wall, 
assumptions were also made about the microthreads. It was assumed that all microthreads 
have the same diameter, length, and elastic modulus. As reported by Cornwell, the error 
reported for the elastic modulus of uncrosslinked microthreads is ± 1.2MPa [19]. 
Although this error is relatively large (30%), this assumption is valid as a first 
approximation. The error reported for the cross-sectional area of microthreads is very 
small (± 5790 µm2) and therefore this assumption is valid. The assumption that all of the 
microthreads had the same length is not entirely valid because the threads are wrapped 
around a sphere. Microthreads that are wrapped around the center of the sphere will be 
longer than those that are wrapped around the ends of the sphere. However, this 
assumption accounts for a very small change in the volume of the microthreads because 
the threads are so small.  
It was expected that more threads would be required in the fiber direction than in 
the cross fiber direction because the stiffness of the heart wall is greater in the fiber 
direction than in the cross fiber direction [95]. The stiffness of the composite material 
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was taken to be 10% greater than the native heart wall because it is expected that a small 
increase in stiffness would provide structural support to prevent dilatation, but at the 
same time would not interfere greatly with the contraction of the healthy myocardium. In 
order to account for a factor of safety or to increase the stiffness of the heart wall-
microthread composite even further, the number of microthreads required could be 
recalculated. Also, the stiffness was increased equally both in the fiber and cross fiber 
directions in order to keep the model relatively simple. However, the stiffness may not 
need to be equally increased in both directions. 
7.4 Cell Migration Assay 
A cell migration assay was performed to observe the migration and proliferation 
of smooth muscle cells (SMCs) with PDGF coated microthreads in comparison to control 
samples. As described in Section 6.4, SMCs were observed surrounding the PDGF coated 
microthreads. Although it appeared that the cells migrated to the thread and subsequently 
proliferated around the thread, cell migration was not apparent when the entire petri dish 
was observed. As seen in Figure 24, which shows a characteristic picture of the entire 
dish seven days after plating, many cells were observed on the side of the dish were the 
cells were initially plated, with very few cells between this side of the dish and the 
microthread. This observation may be attributed to the fact that the PDGF concentration 
was likely very low on the side of the dish where the cells were initially cultured. Since 
the PDGF concentration may have been too low to promote cell migration, the cells 
likely proliferated where they were initially plated, with little migration towards the 
microthread. In order to observe a more significant amount of cell migration, a smaller 
petri dish could be used because the PDGF concentration would not be as low on the side 
of the dish where the cells are plated. 
When performing the cell migration assay, a major problem that was consistently 
observed with each trial was overgrowth of the cells. In all trials, within a week the cells 
had begun to overgrow the petri dish and were observed to lift off the plate in sheets and 
fold over. As previously described, the cells appeared to proliferate on the side of the dish 
where they were initially plated with very little migration to the other side of the dish 
where the microthread was located. The proliferation of cells on one side of the dish 
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caused them to overgrow and lift off the plate in this area. To prevent the overgrowth of 
cells, a smaller petri dish could be used so that the cells are more likely to migrate to the 
microthread before they overgrow the dish. 
In the last trial, very few cells were observed surrounding the PDGF coated 
microthread B. This observation appeared to be an anomaly because all other PDGF 
coated microthreads in all trials were surrounded by cells. When being glued on to the 
tissue culture treated petri dish, this particular thread appeared to be pulled toward the 
dish as if it were attracted by some type of static electricity phenomenon. It was very 
difficult to lay the microthread down in the marked position and once it was laid down, it 
was no longer hydrated. This phenomenon may have affected the ability of this particular 
microthread to promote cell migration and proliferation.  
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8 Conclusions 
By utilizing an engineering design process, a contractile LV restraint device was 
designed, using PANI as the major component of the device. However, preliminary 
testing demonstrated that PANI films could not be manufactured with the appropriate 
material properties. The films could not be doped and could not be removed from the 
glass slides because they were brittle and hard to handle. Additionally, during preliminary 
testing of the contractile properties of PANI slivers, no visible contraction was observed. 
Because PANI could not be doped and did not visually contract with the application of an 
electrical stimulus, it was not a viable material for a contractile LV restraint.  
Since a contractile LV restraint could not be developed within the time 
constraints, preliminary designs were re-evaluated to select a passive restraint design to 
pursue. A mesh restraint was developed with microthreads chosen as the material for the 
device and PDGF selected as the therapeutic agent. Calculations based on the rule of 
mixtures demonstrated that 34 microthreads would be required for the device and 
therefore it would be feasible to build a prototype for future testing. Based on first order 
approximations, a pressure vessel-based equation indicated that the mesh restraint will 
reduce dilatation of the heart. A cell migration assay was performed and demonstrated 
that the migration and proliferation of smooth muscle cells was higher with PDGF coated 
microthreads.  
In this design project, a LV restraint that reduces dilatation and delivers a 
therapeutic agent was developed. Initial calculations demonstrated that the mesh will 
reduce dilatation of the heart. Results from the cell migration assay indicate that the 
device has the potential to promote angiogenesis in vivo. By promoting angiogenesis, the 
device will provide an environment conducive to myocardial regeneration. Additionally, 
since it has previously been shown that microthreads are viable for use in cell delivery, 
regenerative agents, such as stem cells, could also be incorporated into the device to aid 
in the regeneration of the myocardium [19]. Although more research and testing is 
needed to optimize the microthread mesh restraint and ensure its functionality, this design 
project provided an important first step in the development of a microthread mesh 
restraint that promotes angiogenesis.    
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9 Future Recommendations 
This project describes the beginning of the many steps needed to develop a fully 
functional left ventricular restraint device that promotes angiogenesis. Promising results 
have been shown but further investigation is needed to ultimately develop this device for 
use in patients with heart failure.    
9.1 Polyaniline Device 
Initially, PANI was selected as the major component of the device because it 
would provide contractile support to the failing heart. Though the idea seemed promising, 
major problems prevented further development of designs that involved PANI.  
The protocol used produced PANI films that were brittle and hard to handle. 
Uniform PANI films could be produced, however they could not be removed from the 
slide and cracked during the doping process. Additionally, when small pieces of cracked 
PANI films were doped and then electrically stimulated, no visual contraction was 
observed. In order to determine if the PANI films contract when stimulated electrically, 
the set up that was used could be verified or more sophisticated stimulation and detection 
equipment could be used. Since the protocol did not produce uniform films that could be 
doped or contract when stimulated, PANI was not a viable material for this project due to 
time constraints. In order to use PANI in a contractile LV restraint device, further 
investigation is needed to develop a protocol for manufacturing PANI with more 
appropriate material properties. 
9.2 Microthread Device 
 In order to develop a LV restraint that promotes angiogenesis, microthreads 
coated in PDGF were tested for their ability to promote migration and proliferation of 
smooth muscle cells. Results from the cell migration assay demonstrated an increased 
rate of migration and proliferation of smooth muscle cells was higher with the PDGF 
treated microthreads than the control samples. Further testing should be performed to 
quantitatively compare the rate of migration and proliferation on all samples. In order to 
do this, smooth muscle cells could be stained and counted at specific regions of the petri 
 79 
dish at certain time points. Statistical analysis should be performed to verify that the 
increase in migration and proliferation of the cells with the PDGF treated microthreads is 
statistically significant compared to the other samples. Also, further investigation should 
be performed to optimize the concentration of PDGF on the microthreads. Since PDGF is 
expensive, the concentration should as minimal as possible but should still promote cell 
migration and proliferation. The ability of regenerative agents, such as human 
mesenchymal stem cells, to be incorporated into the device should also be investigated.  
 Due to time constraints, a microthread device could not be manufactured and 
mechanical testing could not be performed. The rule of mixtures demonstrated that the 
device will reduce dilatation of the heart wall. However, the rule of mixtures was used as 
a first order approximation and therefore, more complex calculations involving finite 
element analysis could be used to obtain more accurate results. Additionally, 
experimentation should be performed to confirm these findings and to ensure that the 
device can withstand the forces it would be subjected to after implantation. Uniaxial 
tensile testing could be used as a first approximation to characterize the ultimate tensile 
stresses, strains, and fatigue life of the mesh. Following uniaxial testing, multi-axial 
tensile testing should be performed to ensure that the mesh can withstand the orientation 
of the forces within the heart wall. Fatigue testing is vital because the mesh will be 
subjected to repeated loading once implanted.  
In order to determine the safety and efficacy of the device in vivo, testing should 
be performed in small animal models and then large animal models. The ability of the 
device to promote angiogenesis in vivo should be confirmed by examining the blood 
vessel density before and after implantation [10]. Finally, the ability of the mesh to 
provide structural support and prevent dilatation should be confirmed in vivo.  
 The results presented demonstrate that PDGF coated microthreads could be used 
to develop a LV restraint that promotes angiogenesis. Although all the desired testing 
could not be accomplished due to time constraints, this research provides a strong 
foundation for future development in creating a left ventricular restraint device that 
promotes angiogenesis for patients that suffer from heart failure.  
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APPENDIX A – Notes From Stony Brook Trip 
 On December 5, 2007, our MQP team visited The State University of New York 
at Stony Brook to consult with Dr. Pelagia-Irene (Perena) Gouma and her graduate 
student Koushik Ramachandran, who work in the Department of Materials Science and 
Engineering. The main goals of our visit included learning about the procedures and 
equipment used to make electroactive polyaniline (PANI). 
 The team had a meeting with Koushik in which he presented their research 
concerning PANI. He also answered important questions relating to the methods of PANI 
synthesis and other concerns we had based on our literature review on PANI. Koushik 
also demonstrated the procedure used to make PANI films. Specifically, the items listed 
below were explained in the question and answer session with Koushik: 
 
1. There are two types of PANI powders: an emeraldine base or an emeraldine salt. The 
difference between the two is that the salt is conductive whereas the base form is 
insulating. 
2. PANI can be made to contract by two general means: exposure to chemical vapors 
(acetone, hexane, ethanol, etc.) or by the application of an electrical stimulus while 
submerged in an electrolytic solution. 
3. PANI typically must be mixed with other materials, such as cellulose acetate (CA) or 
gelatin, to improve its poor mechanical properties. 
4. The form of PANI they were making consisted of PANI salt with CA in various 
proportions. CA is incorporated into the PANI because previous literature reported 
that it supports cell growth and enhances the mechanical properties of PANI. The 
PANI:CA was dissolved in acetone (solvent) and cast upon a glass slide to form a 
thin film. 
5. The PANI:CA was shown to curl upon chemical stimulation from acetone and 
chemical vapors, but it did not respond to electrical stimulation. Koushik noted that a 
high resistance of 10 kOhm was measured for many of the PANI:CA samples.  
6. In order to make PANI electroactive, the emeraldine base must be dissolved in the 
solvent N-methyl-pyrrolidinone (NMP). The emeraldine salt cannot be used because 
it does not dissolve in the NMP, forming an irregular and discontinuous film when 
cast. 
7. To make the PANI base electroactive it must be doped with chemicals such as 
hydrochloric acid (HCl), camphorsulfonic acid, or m-cresol. The addition of protons 
and changes in state allow the PANI to contract. 
8. As the film becomes thicker, it becomes harder to activate. For PANI:CA that has 
been solvent cast the more solvent used in the procedure, the more porous the 
resulting material becomes and thus it is easier to activate via chemical stimulation. 
 
Procedure for making PANI:CA films:  
1. A 50:50 PANI:CA solution is prepared by dissolving 0.625 g of PANI emeraldine salt 
and 0.625 g of CA in 1 mL of acetone. The resulting solution is 12.5% PANI by 
volume. 
 90 
2. The PANI:CA solution is sonicated for about 10-15 minutes to obtain a uniform 
mixture. 
3. The solution is carefully poured over a glass slide (or other substrate) and spread out 
using a small wooden stick. 
4. The acetone is allowed to evaporate for about 5 minutes.  
5. The thin PANI:CA film is then peeled off using tweezers. 
 
Procedure for making electroactive PANI: 
The procedure for solvent casting the PANI emeraldine base is similar to the 
procedure described above. A solution is mixed using 12% PANI by volume in NMP, 
which is then poured onto a glass slide. The NMP is allowed to evaporate from the PANI 
solution overnight because NMP takes longer to evaporate than acetone. Furthermore, the 
glass slide with the PANI and NMP mixture on it could be exposed to higher 
temperatures to speed up the process of evaporation. After the PANI film is made, it is 
doped using HCl (or another dopant) by submerging it in the dopant for a few minutes. 
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APPENDIX C – Stress Calculations 
In patients with high ventricular pressure, meridional wall stress, σ = 161*103 dyn/cm2 = 
16.1 kPa. Meridional wall stress is defined as the force per unit area acting from the apex 
to base of the heart [87]. 
 
Meridional wall stress can be expressed by the following function: 
 
 wall theoflength  and force, wall , thicknesswall  where, ===
×
== lFt
tl
F
A
F
σ  
 
The average wall thickness for patients with high ventricular pressure, 
0.017mmm 17 ==t [87] 
 
Wall tension, F/l (N/m) can be expressed as: 
t
l
F
×= σ  
 
Incorporating a safety factor (SF) of 5, the wall tension can be calculated: 
N/mm37.15mm17kPa1.16 =××=××= SFt
l
F
σ  
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APPENDIX D – Fatigue Calculations 
A number of studies have reported the mortality rate for patients with heart failure to be 
approximately 59-68% after the first two years. These studies often report the results of 
data obtained from hospitals and therefore typically reflect more severe cases of heart 
failure [89]. Since our device is intended for patients with class III or IV heart failure, we 
believe that this data will accurately reflect the mortality of patients intended to be treated 
with our device. Thus, our device must be able to withstand cyclic loading for a 
minimum of two years.  
 
The heart beats an average of 75 beats/min [21]. The total number of cycles our device 
must withstand is the number of heart beats that occur in two years: 
cycles 000,840,78years 2
yr 1
days 365
day 1
hr 24
hr 1
min 60
min 1
beats 75
=××××  
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APPENDIX E – Conceptual Designs 
Conceptual Design 1: 
 
 A contractile biomaterial, such as PANI, stem cells, and a CorCap™ mesh are 
combined into one device. The PANI aids in systolic contraction and the stem cells serve 
to regenerate the myocardium. The CorCap™ mesh will provide passive restraint to the 
heart. A cell-sustaining “anti-death” solution could be used in place of the stem cells. 
Pros: 
• Improves heart function through a variety of treatments 
• Localized delivery of the therapeutic agent directly to the infarcted area 
Cons: 
• May be difficult to maintain the effectiveness of each individual treatment in a 
combined device 
• May be difficult to simulate contraction that propagates through the mesh like the 
native heart 
• Complex design 
• Regulatory approval of this device may be difficult to obtain 
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Conceptual Design 2: 
 
 A PANI thread splint crosses through the left ventricle from front to back without 
passing through the septum and is sutured to the myocardium on each end. An electrical 
stimulus from a pacemaker causes the PANI thread to contract during systole.  
Pros: 
• Simple design 
Cons: 
• Passive restraint provided by the thread splint may be limited 
• The amount of contractile assistance may be limited in this configuration 
• The thread may disrupt myocardium function 
• Splint may induce blood clot formation 
 
Conceptual Design 3: 
 
 PANI threads are cross-stitched and sutured into place in the infarcted area of the 
heart. An electrical stimulus causes the PANI to contract during systole. 
Pros: 
• Localized delivery and contractile assistance 
• Similar to heart patches, which have been thoroughly tested 
Cons: 
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• Surgical cross-stitching of the PANI may be difficult 
• Sutures in the infarcted area may cause further damage 
• The amount of contractile assistance may be limited by this configuration 
 
Conceptual Design 4: 
 
 A modified left ventricular assist device is used in conjunction with PANI. A 
PANI hoop is wrapped around the heart and is chemically stimulated to contract by 
alcohol. A modified LVAD contains a special fluid circuit that delivers the alcohol to the 
PANI.  
 
Pros: 
• High probability of beneficial LV remodeling due to generous unloading of the 
LV 
Cons: 
• Complex design 
• Alcohol could leak from the fluid circuit and cause toxicity 
• It may be expensive to modify a LVAD to circulate alcohol 
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Conceptual Design 5:  
 
 A PANI thread splint crosses through the left ventricle from front to back without 
passing through the septum near the site of the infarction. It is attached to two end pads, 
which serve to anchor the splint on the heart and hold a therapeutic treatment. The 
therapeutic treatment, such as stem cells, will regenerate the heart tissue while the PANI 
splint provides contractile assistance and passive restraint.  
Pros: 
• The epicardial pads can be tailored to various infarct sizes 
• Localized delivery of the therapeutic agent directly to the infarcted area 
Cons: 
• The thread may disrupt myocardium function 
• May be difficult to attach PANI to the end pads 
• The splint may induce blood clot formation 
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Conceptual Design 6: 
 
 PANI strips are arranged in hoops around the circumference of the heart from its 
apex to the atrioventricular groove. A programmed electrical stimulus causes the PANI 
hoops to contract starting with the one closest to the apex. The PANI hoops also provide 
passive restraint for the heart during diastole. 
Pros: 
• A high degree of contractile assistance is provided by this configuration 
Cons: 
• It may be difficult to contract each hoop at the appropriate time, resulting in 
arrhythmias 
• Contraction of the device may produce right ventricular dysfunction due to 
unloading 
• It may be difficult to incorporate a therapeutic agent into this design 
 
Conceptual Design 7: 
 
 A CorCap™ mesh is combined with a collagen sponge and therapeutic treatments 
such as growth factors or stem cells. The CorCap™ mesh provides passive restraint and 
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serves as a platform for the collagen sponge. The collagen sponge with the therapuetic 
agent is embedded into the mesh around the site of the infarction.  
Pros: 
• Localized delivery of the therapeutic agent directly to the infarcted area 
• Can be biodegradable 
Cons: 
• Does not provide contractile assistance 
• Embedding the sponge and treatment agent into the mesh at the site of the infarct 
may be difficult 
 
Conceptual Design 8: 
 
 A fibrin glue scaffold containing PANI is made in vitro. The scaffold is then 
injected into the patient and then either formed into a patch over the infarcted area or a 
wrap. The PANI is electrically stimulated to contract during systole. 
Pros: 
• Simple implantation and delivery procedure 
• A number of shapes and forms can be made from injectable fibrin glue 
Cons: 
• Preparation of PANI-impregnated fibrin glue may be difficult 
• It may be difficult to obtain an optimal PANI fiber arrangement upon injection of 
the fibrin gel 
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Conceptual Design 9: 
 
A mesh similar to the CorCap design is made from a passive material, such as 
microthreads. Growth factors or cells are incorporated into the microthreads that will be 
placed over the infarcted area.  
Pros: 
• Simple implantation procedure 
• Will provide a large degree of structural support 
• Local delivery of therapeutic agent to the infarcted area 
Cons: 
• May be difficult to construct the intricacies of the mesh design 
• No contractile support 
 
 
A mesh is made from a passive material, such as microthreads. Unlike the wrap 
design, the mesh will act as a band and will not wrap around the entire heart. Growth 
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factors or cells are incorporated into the microthreads that will be located directly over 
the infarcted area.  
Pros: 
• Simple implantation procedure 
• Simple construction 
• Local delivery of therapeutic agent to the infarcted area 
Cons: 
• Will not provide as much mechanical support as the mesh design 
• No contractile support 
 
 
 
A patch is made from a passive material, such as microthreads. Growth factors or 
cells are incorporated into the microthreads.  
Pros: 
• Local delivery of the therapeutic agent to the infarcted area 
• The patch can be constructed more easily than the mesh or band design 
Cons: 
• May be difficult to attach to the heart 
• Will provide little structural support 
• No contractile support 
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APPENDIX F– Evaluation Matrix 
Using the constraints and objectives identified in Section 4.2, an evaluation 
matrix was used to evaluate the most feasible design alternatives. To evaluate the 
constraints, a yes or no question was used to determine if the design met the applied 
constraints. If the design would not meet the constraint, it was not considered a viable 
design alternative. For each objective, the designs were given a score of 0 to 5, where a 
rating of 0 indicated that the design would not meet the objective at all and 5 indicated 
that the design would completely meet the objective. For each objective and constraint, 
the basis for evaluation is described below. 
 
Constraint: Biocompatible 
Basis for evaluation: The ability of the device to not induce an inflammatory response 
and to be non-toxic and hemocompatible. 
 
Constraint: Cost ($624) 
Basis for evaluation: The materials for the device and manufacturing cost must be under 
$624. 
 
Constraint: Time (April, 2008): 
Basis for evaluation: It must be feasible to manufacture and test the design within the 
given time constraint. 
 
Objective: Minimal cost 
Basis for evaluation: The ability of the design to be produced at the lowest cost possible, 
which is dependent on the cost of the individual materials, their availability, and the 
expenses incurred in processing/testing them. 
 
Objective: Available materials 
Basis for evaluation: The ability of the design to incorporate easily obtainable materials. 
 
Objective: Appropriate mechanical properties 
Basis for evaluation: The ability of the device to provide the necessary mechanical 
support and have the necessary tensile strength, elastic properties, fatigue, and wear 
resistance. 
 
Objective: Simple implantation procedure 
Basis for evaluation: The ability of the device to be easily implantable, compatible with 
current surgical techniques, and require a short patient recovery time. 
 
Objective: Easily produced 
Basis for evaluation: The ability of the device to be manufactured easily and quickly 
with as few steps as possible. 
 
Objective: Appropriate contractile properties 
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Basis for evaluation: The ability of the device to contract with the native heart, without 
producing arrhythmias.  
 
Constraints and 
Objectives Weight 
Contractile 
biomaterial, 
wrap restraint, 
and cells or 
growth factors 
Contractile 
biomaterial, nut 
& bolt restraint, 
and cells or 
growth factors 
on end caps 
Contractile 
biomaterial, 
hoops or strips, 
cells or growth 
factors 
Contractile 
biomaterial, 
patch, cells or 
growth factors 
Passive wrap 
restraint with 
cells or growth 
factors 
C: Biocompatible --- Y Y Y Y Y 
C: Cost ($624) --- Y Y Y Y Y 
C: Time (April, 2008) --- Y Y Y Y Y 
O: Minimal Cost 4.8% 3(0.048)=0.144 3(0.048)=0.144 3(0.048)=0.144 4(0.048)=0.192 3(0.048)=0.144 
O: Available Materials 16.7% 2(0.167)=0.334 2(0.167)=0.334 2(0.167)=0.334 2(0.167)=0.334 4(0.167)=0.668 
O: Appropriate 
Mechanical Properties 28.6% 4(0.286)=1.144 3(0.286)=0.858 2(0.286)=0.572 1(0.286)=0.286 4(0.286)=1.14 
O: Simple 
Implantation 
Procedure 9.5% 4(0.095)=0.38 2(0.095)=0.19 3(0.095)=0.285 3(0.095)=0.285 3(0.095)=0.285 
O: Easily Produced 16.7% 2(0.167)=0.334 3(0.167)=0.501 4(0.167)=0.668 4(0.167)=0.668 2(0.167)=0.334 
O: Appropriate 
Contractile Properties 23.8% 2(0.238)=0.467 4(0.238)=0.952 2(0.238)=0.476 3(0.238)=0.952 0(0.238)=0 
TOTAL 100% 2.803 2.979 2.479 2.717 2.575 
 
 
Constraints and 
Objectives Weight 
Passive band 
restraint with 
cells or growth 
factors 
Passive patch 
with cells or 
growth factors 
Contractile 
biomaterial, 
LVAD 
Passive wrap 
restraint, 
collagen 
sponge to hold 
growth factors 
or cells 
Contractile 
biomaterial and 
fibrin glue, 
patch, wrap, or 
band 
C: Biocompatible --- Y Y Y Y Y 
C: Cost ($624) --- Y Y N Y Y 
C: Time (April, 2008) --- Y Y N N N 
O: Minimal Cost 4.8% 3(0.048)=0.144 4(0.048)=0.192 N/A N/A N/A 
O: Available Materials 16.7% 4(0.167)=0.668 4(0.167)=0.668 N/A N/A N/A 
O: Appropriate 
Mechanical Properties 28.6% 2(0.286)=0.572 1(0.286)=0.286 N/A N/A N/A 
O: Simple 
Implantation 
Procedure 9.5% 4(0.095)=0.380 3(0.095)=0.285 N/A N/A N/A 
O: Easily Produced 16.7% 4(0.167)=0.668 4(0.167)=0.668 N/A N/A N/A 
O: Appropriate 
Contractile Properties 23.8% 0(0.238)=0 0(0.238)=0 N/A N/A N/A 
TOTAL 100% 2.432 2.099 N/A N/A N/A 
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Explanation of Evaluation 
Design #1: Contractile biomaterial, wrap restraint, and cells or growth factors 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (Y) It is feasible to manufacture and test the design within the given time 
frame. 
• Minimal cost – (3) The materials should be able to be purchased and processed at 
a relatively low cost. However, since the mesh encloses the entire heart, a large 
amount of material may be utilized, which would increase the cost of producing 
the device. 
• Available materials – (2) The materials for the device are available for purchase, 
but may require a significant amount of processing and manufacturing. 
• Appropriate mechanical properties – (4) The wrap restraint will provide a large 
amount of mechanical support because it prevents expansion of the entire heart. 
• Simple implantation procedure – (4) The restraint will be implanted by wrapping 
it around the heart and then securing it to the heart. This can be done using a 
minimally invasive surgical technique and will therefore require a short patient 
recovery time. 
• Easily produced – (2) It will be difficult to produce the intricacies of the complex 
mesh design. The contractile biomaterials may be difficult to be made into a 
mesh. 
• Appropriate contractile properties – (2) It will be difficult to simulate a 
contraction that propagates through the mesh similar to the propagation of 
contraction through the native heart. 
Design #2: Contractile biomaterial, nut & bolt restraint, and cells or growth factors on 
end caps 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (Y) It is feasible to manufacture and test the design within the given time 
frame. 
• Minimal cost – (3) The materials should be able to be purchased and processed at 
a relatively low cost. However, since this design incorporates two different parts 
(the splint and end cap) and potentially two different types of materials, additional 
costs in combining these parts or materials may be incurred. 
• Available materials – (2) The materials for the device are available for purchase, 
but may require a significant amount of processing and manufacturing. 
• Appropriate mechanical properties – (3) The nut & bolt restraint will provide 
limited mechanical support. Also, stress concentrations may result at the interface 
between the end caps and the splint. 
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• Simple implantation procedure – (2) The device will be very difficult to implant 
because the splint will penetrate the ventricular wall. Also, patient recovery time 
may be prolonged due to the invasiveness of this design. 
• Easily produced – (3) The parts of the nut and bolt design can be more easily 
produced than the mesh design. However, incorporating the end caps onto the 
ends of the splint will be difficult. 
• Appropriate contractile properties – (4) The contraction of this device will be 
easiest to control because the propagation of the contraction does not need to be 
as precisely controlled as with the mesh. 
Design #3: Contractile biomaterial, hoops or strips, cells or growth factors 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (Y) It is feasible to manufacture and test the design within the given time 
frame. 
• Minimal cost – (3) The materials should be able to be purchased and processed at 
a relatively low cost.  
• Available materials – (2) The materials for the device are available for purchase, 
but may require a significant amount of processing and manufacturing. 
• Appropriate mechanical properties – (2) The hoops or strips will provide limited 
mechanical support. 
• Simple implantation procedure – (3) The device can be implanted relatively 
simply by wrapping the hoops or strips around the heart. 
• Easily produced – (4) The hoops or strips can be produced much more easily than 
the other design alternatives. 
• Appropriate contractile properties – (2) The propagation of contraction will be 
difficult to control if there are multiple hoops or strips. 
Design #4: Contractile biomaterial, patch, cells or growth factors 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (Y) It is feasible to manufacture and test the design within the given time 
frame. 
• Minimal cost – (4) The materials should be able to be purchased and processed at 
a relatively low cost. This design has the highest rating because the patch will 
require a very small amount of material. 
• Available materials – (2) The materials for the device are available for purchase, 
but may require a significant amount of processing and manufacturing. 
• Appropriate mechanical properties – (1) The patch will provide little mechanical 
support to the entire heart because it will be placed only over the infarct. 
• Simple implantation procedure – (3) The device may be difficult to attach to the 
heart because it will only be held in place by suturing.  
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• Easily produced – (4) The simple design of the patch can be produced relatively 
easily. 
• Appropriate contractile properties – (3) The propagation of contraction will not 
need to be precisely controlled due to the localized nature of the patch. 
Design #5: Passive wrap restraint with cells or growth factors 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (Y) It is feasible to manufacture and test the design within the given time 
frame. 
• Minimal cost – (3) The materials should be able to be purchased and processed at 
a relatively low cost.  
• Available materials – (4) The materials for the device are available for purchase 
and may require some processing and manufacturing.  
• Appropriate mechanical properties – (4) The wrap restraint will provide the 
necessary mechanical support to the entire heart. 
• Simple implantation procedure – (3) The restraint will be implanted by wrapping 
it around the heart and then securing it to the heart. This can be done using a 
minimally invasive surgical technique and will therefore require a short patient 
recovery time. 
• Easily produced – (2) It may be difficult to produce the intricacies of the complex 
mesh design.  
Design #6: Passive band restraint with cells or growth factors 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (Y) It is feasible to manufacture and test the design within the given time 
frame. 
• Minimal cost – (3) The materials should be able to be purchased and processed at 
a relatively low cost.  
• Available materials – (4) The materials for the device are available for purchase 
and may require some processing and manufacturing.  
• Appropriate mechanical properties – (2) The band restraint will provide some 
mechanical support, but may cause bulging at the top and bottom of the band. 
• Simple implantation procedure – (4) The restraint will be implanted by wrapping 
it around the heart and then securing it to the heart. This can be done using a 
minimally invasive surgical technique and will therefore require a short patient 
recovery time. 
• Easily produced – (4) The device will be easier to manufacture than the wrap 
restraint because it is a bit more simplistic in design. 
Design #7: Passive patch with cells or growth factors 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
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• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (Y) It is feasible to manufacture and test the design within the given time 
frame. 
• Minimal cost – (4) The materials should be able to be purchased and processed at 
a relatively low cost. The patch will require a smaller amount of material and thus 
a lower cost than other design alternatives. 
• Available materials – (4) The materials for the device are available for purchase 
and may require some processing and manufacturing.  
• Appropriate mechanical properties – (1) The patch will provide limited 
mechanical support because it will be placed only over the infarct.  
• Simple implantation procedure – (3) The device may be difficult to attach to the 
heart because it will only be held in place by suturing.  
• Easily produced – (4) The simple design of the patch can be produced relatively 
easily. 
Design #8: Contractile biomaterial, LVAD 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (N) The materials and manufacturing processes required are not expected 
to be within the project budget of $624. 
• Time – (N) It is not feasible to manufacture and test the design within the given 
time frame. 
Design #9: Passive wrap restraint, collagen sponge to hold growth factors or cells 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (N) It is not feasible to manufacture and test the design within the given 
time frame. 
Design #10: Contractile biomaterial and fibrin glue, patch, wrap, or band 
• Biocompatible – (Y) The device is expected to be non-toxic, hemocompatible, 
and to not induce an inflammatory response. 
• Cost – (Y) The materials and manufacturing processes required are expected to be 
within the project budget of $624. 
• Time – (N) It is not feasible to manufacture and test the design within the given 
time frame. 
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APPENDIX G- Protocols for Cell Culture 
 
Culturing Human Mesenchymal Stem Cells (HMSCs) 
 
Purpose 
 
 
To culture HMSCs for biocompatibility testing.  
 
Specifications 
 
 
N/A 
 
Materials and 
Equipment 
 
Materials 
• Dulbecco’s Modified Eagle Medium (DMEM) 
• 10% fetal bovine serum (FBS) 
• T-75 culture flasks 
• 0.25% trypsin 
• Hank’s Balance solution 
• Sterile pipettes: 10mL, 1mL  
• Aspirating pipettes  
• 70% ethanol  
 
Equipment 
• Sterile hood 
• Light microscope 
 
 
Procedure 
Culturing Cells 
1. Spray ethanol in hood and wipe down to disinfect area. 
2. Aspirate all media from cell culture flask. Do not pass 
hands over any opened containers because this may 
contaminate the solutions. 
3. Fill culture flask with 10mL of fresh media. 
4. Observe cells under a microscope to see if they are 
attached.  
5. Feed cells approximately every 3-4 days. 
Splitting Cells 
1. Spray ethanol in hood and wipe down to disinfect area  
2. Aspirate all media from cell culture flask. Do not pass 
hands over any opened containers because this may 
contaminate the solutions.  
3. Rinse flask with either 10mL of Hank’s Balance solution or 
DMEM. 
4. Add 1mL of trypsin. 
5. Place flask under microscope and watch for cells to detach 
(approximately 2-3 minutes). 
6. Once most of the cells are visibly detached, add cell culture 
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media with 10% FBS.  
7. Pipette cells and media into a centrifuge tube and agitate 
them. 
8. Place in centrifuge at 600RPMs for 3 minutes to spin the 
cells down.  
9. Aspirate the media and add in 10mL of fresh media.  
10. Re-suspend/aliquot cells into desired number of flasks and 
add cell media for a total volume of 10mL.  
11. Feed cells 24 hours after splitting and check under 
microscope to ensure that the cells have plated and no 
contamination has occurred.  
 
 
Expected 
Results 
 
 
N/A 
 
Methods of 
Analysis 
 
 
N/A 
 
References 
 
 
Protocol obtained from Professor Gaudette’s laboratory 
 
Culturing Rat Aortic Smooth Muscle Cells (SMCs) 
 
Purpose 
 
 
To culture SMCs for cell migration assays with microthreads. 
 
Specifications 
 
 
N/A 
 
Materials and 
Equipment 
 
Materials 
• Dulbecco’s Modified Eagle Medium (DMEM) 
• 10% fetal bovine serum (FBS) 
• T-75 culture flasks 
• 0.25% trypsin 
• Hank’s Balance solution 
• Sterile pipettes: 10mL, 1mL  
• Aspirating pipettes  
• 70% ethanol  
 
Equipment 
• Sterile hood 
• Light microscope 
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Procedure 
Culturing Cells 
1. Spray ethanol in hood and wipe down to disinfect area. 
2. Aspirate all media from cell culture flask. Do not pass 
hands over any opened containers because this may 
contaminate the solutions. 
3. Fill culture flask with 10mL of fresh media. 
4. Observe cells under a microscope to see if they are 
attached.  
5. Feed cells approximately every 2 days. 
Splitting Cells 
1. Spray ethanol in hood and wipe down to disinfect area  
2. Aspirate all media from cell culture flask. Do not pass 
hands over any opened containers because this may 
contaminate the solutions.  
3. Rinse flask with either 10mL of Hank’s Balance solution or 
DMEM. 
4. Add 1mL of trypsin. 
5. Place flask under microscope and watch for cells to detach 
(approximately 7 minutes). 
6. Once most of the cells are visibly detached, add cell culture 
media with 10% FBS.  
7. Pipette cells and media into a centrifuge tube and agitate 
them. 
8. Place in centrifuge at 600RPMs for 3 minutes to spin the 
cells down.  
9. Aspirate the media and add in 10mL of fresh media.  
10. Re-suspend/aliquot cells into desired number of flasks and 
add cell media for a total volume of 10mL.  
11. Feed cells 24 hours after splitting and check under 
microscope to ensure that the cells have plated and no 
contamination has occurred.  
 
 
Expected 
Results 
 
 
N/A 
 
Methods of 
Analysis 
 
 
N/A 
 
References 
 
 
Protocol obtained from Professor Rolle’s laboratory 
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APPENDIX H – Protocol for Producing PANI films 
 
Solvent Casting Polyaniline Films 
 
Purpose 
 
 
To produce thin films of polyaniline. 
 
Specifications 
 
N/A 
 
 
Materials and 
Equipment 
 
Materials 
• Emeraldine base polyaniline, average Mw of 10kD  
• N-methyl-2-pyrrolidone, biotech grade  
• 1M HCl 
• PBS 
• Drierite 
• Parafilm 
• Petri dishes 
• Glass slides 
• Micropipette and tips 
 
Equipment  
• Fume hood 
• Shaker 
• Vacuum chamber 
• Tweezers 
• Small bottles with caps 
• Nitrogen tank 
 
 
Procedure 
 
Making PANI:NMP solution 
1. Mix 12% wt/vol of PANI in NMP in a small bottle with a cap 
2. Place the bottle on the shaker to dissolve overnight. 
3. Store remaining PANI in an inert gas environment by adding 
nitrogen gas to the bottle, sealing it with parafilm, and placing 
the bottle in a vacuum chamber containing drierite. 
 
Pouring PANI:NMP solutions onto casting surface 
1. Place 1-2mL of PANI solution onto each glass slide using a 
micropipette. 
2. Leave the slides in a fume hood overnight to allow for 
evaporation of the NMP solvent. 
 
Doping of PANI films 
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1. Remove dry PANI films from each slide using tweezers. 
2. Wash the films 3 times with PBS for 5 min. 
3. Place each film in a petri dish. 
4. Pour 1M HCl in each petri dish until the film is submerged. 
5. Remove the films using tweezers after 15 min of doping. 
6. Place films in another petri dish to dry. 
 
Expected 
Results 
 
 
Thin films of electroactive PANI 
 
Methods of 
Analysis 
 
 
N/A 
 
 
References 
 
 
Protocol obtained from Dr. Gouma’s laboratory at Stony Brook 
University (Appendix A) 
 
 
Solvent Casting Polyaniline Films, Revised 1/21/08 
 
Purpose 
 
 
To produce thin films of polyaniline. 
 
Specifications 
 
N/A 
 
 
Materials and 
Equipment 
 
Materials 
• Emeraldine base polyaniline, average Mw of 10kD  
• N-methyl-2-pyrrolidone, biotech grade  
• 1M HCl 
• PBS 
• Small bottles with caps 
• Four-well chamber slides 
• 12mm tissue culture discs coated with poly-D-lysine 
• Tape 
• Micropipette and tips 
• Parafilm 
• Drierite 
• Petri dish 
• Small bottles with caps 
 
Equipment 
• Fume hood 
• Shaker 
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• Vacuum chamber 
• Box cutter 
• Tweezers 
• Nitrogen tank 
 
 
Procedure 
 
Making PANI:NMP solution 
1. Mix solutions of 12% wt/vol and 4% wt/vol of PANI in NMP in 
a small bottle with a cap. 
2. Place the bottle on the shaker to dissolve overnight. 
3. Store remaining PANI in an inert gas environment by adding 
nitrogen gas to the bottle, sealing it with parafilm, and placing 
the bottle in a vacuum chamber containing drierite. 
 
Pouring PANI:NMP solutions onto casting surface 
1. Use a box cutter to make holes in the cover of a petri dish. 
2. Put each chamber slide and tissue culture disc into a petri dish 
cover or bottom. 
3. With chamber slides, pour 1-2mL of 4% wt/vol PANI solution 
into each well using a micropipette. 
4. Repeat step 3 with 12% wt/vol PANI solution. 
5. With tissue culture discs, pour 35µL of 4% wt/vol PANI 
solution onto the disc using a micropipette. 
6. Repeat step 5 with 12% wt/vol PANI solution. 
7. Place a cover on the petri dish and place tape around the crease 
to seal the top and bottom halves. 
8. Leave the dish in a fume hood to allow for evaporation of the 
NMP solvent. 
 
Doping of PANI films 
1. Remove dry PANI films from each chamber slide using 
tweezers. 
2. Wash the films 3 times with PBS for 5 min. 
3. Place each film in a petri dish. 
4. Pour 1M HCl in each petri dish until the film is submerged. 
5. Remove the films using tweezers after 15 min of doping. 
6. Place films in another petri dish to dry. 
 
Expected 
Results 
 
 
Thin films of electroactive PANI 
 
Methods of 
Analysis 
 
 
N/A 
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References 
 
[91, 92] 
 
Solvent Casting Polyaniline Films, Revised 1/29/08 
 
Purpose 
 
 
To produce thin films of polyaniline. 
 
Specifications 
 
N/A 
 
 
Materials and 
Equipment 
 
Materials 
• Emeraldine base polyaniline, average Mw of 10kD  
• N-methyl-2-pyrrolidone, biotech grade  
• 1M HCl 
• PBS 
• Glass slides 
• 12mm tissue culture discs coated with poly-D-lysine 
• Micropipette and tips 
• Parafilm 
• Drierite 
• Petri dish 
 
Equipment 
• Small bottles with caps 
• Shaker 
• Fume hood 
• Plastic container 
• Vacuum chamber 
• Tweezers 
• Nitrogen tank 
 
 
Procedure 
 
Making PANI:NMP solution 
1. Mix 4% wt/vol of PANI in NMP in a small bottle with a cap 
2. Place the bottle on the shaker to dissolve overnight. 
3. Store remaining PANI in an inert gas environment by adding 
nitrogen gas to the bottle, sealing it with parafilm, and placing 
the bottle in a plastic container filled with nitrogen gas and 
drierite. 
 
Pouring PANI:NMP solutions onto casting surface 
1. Place the tissue culture discs on glass slides. 
2. Add 35µL of the 4% wt/vol of PANI solution onto the discs 
using a micropipette. 
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3. To ensure uniform diffusion of NMP out of solution, place 
some of the slides in a vacuum chamber, applying a light 
vacuum and allowing the air to circulate throughout the 
chamber (either using a splitter pipe or cracking the chamber 
open slightly). 
4. Place the other slides in the fume hood. 
5. Leave the slides in the vacuum chamber or fume hood overnight 
to allow diffusion of the NMP solvent. 
 
Doping of PANI films 
1. Place the slides containing dry PANI films into a petri dish. 
2. Wash 3 times with PBS for 5 min. 
3. Place the slides into another petri dish and pour 1M HCl in the 
dish until the slides are submerged. 
4. Remove the slides using tweezers after 15 min of doping. 
5. Place the slides in another petri dish to dry. 
 
Expected 
Results 
 
 
Thin films of electroactive PANI 
 
Methods of 
Analysis 
 
 
N/A 
 
 
References 
 
 
[91, 92] 
 
Solvent Casting Polyaniline Films, Revised 1/31/08 
 
Purpose 
 
 
To produce thin films of polyaniline. 
 
Specifications 
 
N/A 
 
 
Materials and 
Equipment 
 
Materials 
• Emeraldine base polyaniline, average Mw of 10kD  
• N-methyl-2-pyrrolidone, biotech grade  
• 1M HCl 
• PBS 
• Glass slides 
• Parafilm 
• Drierite 
• Petri dish 
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• Micropipette with tips 
 
Equipment 
• Small bottles with caps 
• Shaker 
• Fume hood 
• Plastic container 
• Vacuum chamber 
• Tweezers 
 
 
Procedure 
 
Making PANI:NMP solution 
1. Mix 4% wt/vol of PANI in NMP in a small bottle with a cap. 
2. Place the bottle on the shaker to dissolve overnight. 
3. Store remaining PANI in an inert gas environment by adding 
nitrogen gas to the bottle, sealing it with parafilm, and placing 
the bottle in a plastic container filled with nitrogen gas and 
drierite. 
 
Pouring PANI:NMP solutions onto casting surface 
1. Add 300µL of the 4% wt/vol of PANI solution onto the slides 
using a micropipette. 
2. To ensure uniform diffusion of NMP out of solution, place the 
slides in a vacuum chamber, applying a light vacuum and 
allowing the air to circulate throughout the chamber (either 
using a splitter pipe or cracking the chamber open slightly). 
3. Leave the slides in the vacuum chamber overnight to allow 
diffusion of the NMP solvent. 
 
Doping of PANI films 
1. Place the slides containing dry PANI films into a petri dish. 
2. Wash 3 times with PBS for 5 min. 
3. Place the slides into another petri dish and pour 1M HCl in the 
dish until the slides are submerged. 
4. Remove the slides using tweezers after 15 min of doping. 
5. Place the slides in another petri dish to dry. 
 
Expected 
Results 
 
 
Thin films of electroactive PANI 
 
Methods of 
Analysis 
 
 
N/A 
 
 
References 
 
[91, 92] 
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Solvent Casting Polyaniline Films – Optimal Protocol 
 
Purpose 
 
 
To produce thin films of polyaniline. 
 
Specifications 
 
N/A 
 
 
Materials and 
Equipment 
 
Materials 
• Emeraldine base polyaniline, average Mw of 10kD  
• N-methyl-2-pyrrolidone, biotech grade  
• 1M HCl 
• PBS 
• Glass slides and/or 12mm glass tissue culture discs 
• Micropipette with tips 
• Parafilm 
• Drierite 
• Petri dish 
 
Equipment 
• Small bottles with caps 
• Shaker 
• Vacuum chamber 
• Tweezers 
 
 
Procedure 
 
Making PANI:NMP solution 
1. Mix 4 wt%/vol of PANI in NMP in a small bottle with a cap. 
2. Place the bottle on the shaker to dissolve overnight. 
3. Store remaining PANI in an inert gas environment by adding 
nitrogen gas to the bottle, sealing it with parafilm, and placing 
the bottle in container filled with nitrogen gas and drierite. 
 
Pouring PANI:NMP solutions onto casting surface 
1. If using 12mm tissue culture discs, place 35µL of the solution 
onto the discs using a micropipette. 
2. If using glass slides place 300µL of the solution onto the slides 
using a micropipette. 
3. To ensure uniform diffusion of NMP out of solution, place the 
slides or discs in a vacuum chamber, applying a light vacuum 
and allowing the air to circulate throughout the chamber (either 
using a splitter pipe or cracking the chamber open slightly). 
4. Leave the discs and/or slides in the vacuum chamber overnight 
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to allow diffusion of the NMP solvent. 
 
Doping of PANI films 
1. Place the discs and/or slides containing dry PANI films into a 
petri dish. 
2. Wash 3 times with PBS for 5 min. 
3. Pour 1M HCl in the petri dish until the discs or slides are 
submerged. 
4. Remove the discs/slides using tweezers after 15 min of doping. 
 
Expected 
Results 
 
 
Thin films of electroactive PANI 
 
Methods of 
Analysis 
 
 
N/A 
 
 
References 
 
 
[91, 92] 
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APPENDIX I– Protocol to Test the Contractile Properties of 
PANI 
 
Contractile Testing of PANI 
 
Purpose 
 
 
To determine the contractile properties of PANI 
 
Specifications 
 
• Contraction rate of 75 beats/min [21] 
• Contraction duration < 0.3s [21] 
 
 
Materials and 
Equipment 
 
Materials 
• PANI films 
• PBS 
• Petri dish 
• Tape 
 
Equipment 
• Grass stimulator 
• High speed camera 
• Wires (stripped at ends) 
 
 
Procedure 
 
Setup 
1. Tape one end of the wires onto the bottom of the petri dish such 
that they are opposite each other with about 2in in between. 
2. Place the other end of the wires into the output terminals of the 
Grass stimulator. 
3. Pour PBS in the petri dish and place the film of PANI in line 
with the wires, making sure that the PANI is submerged. 
 
Test for visual contraction 
1. Using a single pulse trigger with a pulse duration of 150ms 
start. at 1V and slowly increase the voltage in increments of 
0.5V up to 10V. 
2. Repeat step 1 until a visual contraction is observed. 
 
Measuring the contraction length and time 
1. Place markers on the PANI strip and apply an electrical 
stimulus as described previously. 
2. Record the contraction with a high speed camera and calculate 
the change in length. 
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3. From the video recording, determine the contraction duration. 
 
Determining the contraction force 
1. Setup the experiment as described above and attach a force 
transducer to the PANI. 
2. Apply an electrical stimulus to the PANI and observe the 
maximum force during contraction. 
 
 
Expected 
Results 
 
 
The force, duration, and length of contraction of PANI films 
 
Methods of 
Analysis 
 
 
N/A 
 
 
References 
 
 
None 
 
 
 121 
APPENDIX J-Protocol for Manufacturing Microthreads 
 
Making Soluble Collagen Type I Microthreads 
 
Purpose 
 
 
To make acid-soluble type I collagen threads  
 
Specifications 
 
 
N/A 
 
Materials and 
Equipment 
 
Materials 
• 3mL of collagen solution obtained from rat tail tendon 
• 500mL of FFB (fiber formation buffer) 
• 500mL of FIB (fiber incubation buffer) 
• 5mM HCl 
 
Equipment 
• Extrusion pump 
• Forceps 
• Glass trays (approximately 1in by 2inc) 
• Water bath 
• 0.86mm inner diameter polyethylene tubing  
• Rotating vessel 
• Cardboard box 
 
 
Procedure 
Preparation 
1. Obtain collagen solution by processing rat tail tendon. 
2. Dissolve collagen solution in 5mM HCl (final concentration of 
10mg/mL) in a rotating vessel at 4°C. 
Extruding threads 
1. Turn on water bath and set to 37°C. 
2. Place glass tray filled with 500mL of FFB in water bath. 
3. Using the syringe, take up ~3mL of collagen solution. Attach 
the polyethylene tubing to the syringe and connect the syringe 
to the extrusion pump. Note: Avoid taking up non-dissolved 
solute into the syringe as it will clog the tubing. 
4. Set the extrusion pump to a volume of 3mL with 
0.4mL/minute and turn on.  
5. Once collagen solution reaches the end of the tubing, slowly 
drag the tip over the bottom of the tray from one end to the 
other. Note: It may be difficult to see the microthread coming 
out and the speed at which the tip should be dragged is 
relative to the speed of the collagen traveling through the tube.   
6. After the desired number of microthreads is extruded, cover 
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the glass tray with saran wrap. Cover the water bath and wait 
for 24 hours. 
7. Move the microthreads to FIB for 24 hours. 
8. Take out microthreads using forceps and hang them on the 
edges of a cardboard box overnight.   
 
Expected 
Results 
 
 
Acid-soluble collagen threads (about 20cm in length and 50µm in 
diameter.  
 
Methods of 
Analysis 
 
 
N/A 
 
References 
 
 
[19] 
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APPENDIX K-Microthread Mesh Calculations  
The equation for the rule of mixtures with a constant strain model is: 
K+++= 332211C VEVEVEE  [Eq. 1] 
In Eq. 1, EC is the stiffness of the composite material, Ketc ,V ,V ,V 321  are the volume 
fractions of each constituent material, and Ketc ,E ,E ,E 321  are the stiffnesses of each 
constituent material. The volume fraction of each material is the fraction of the total 
volume that the material occupies [90]. 
In this case, the composite material consists of the heart wall and a microthread mesh. 
Thus, Eq. 1 can be written as follows: 
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In Eq. 2 EC = composite stiffness, VH = volume of the heart wall, VT = volume of the 
microthreads, EH = stiffness of the heart wall, ET = stiffness of the microthreads. Since 
the microthreads will be wrapped around the entire length of the heart, the length of the 
threads is equal to the length of the heart and thus the volume fraction can be simplified 
to an area fraction: 
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The following assumptions were made to simply the calculations: 
• The heart is a hollow sphere 
• All microthreads have the same properties (length, cross-sectional area, 
and stiffness) 
• The stiffness of the right and left ventricles is the same 
• The heart wall is linear elastic 
• The stiffness of the heart wall is constant in the direction of the fibers and 
is constant in the direction perpendicular to the fibers.  
• Fibers in the heart wall run vertically from apex to base 
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In order to better visualize the cross-sectional area of each material within the 
composite, a cross-sectional view of the heart wall was drawn and can be seen in Figure 
26. 
 
Figure 26: Cross-Sectional View of the Composite Material 
Since the heart was assumed to be spherical, the cross-sectional area of the wall was 
calculated by subtracting the area of inner circle from the area of the outer circle: 
( )2i2oH r - rA π=  [Eq. 4] 
The area of the microthreads was calculated by multiplying the cross-sectional area of 
one thread (AC) by the total number of threads (N): 
NAA CT =  [Eq. 5] 
From Hooke’s law for springs in parallel, the total stiffness of the system is the sum of 
the stiffness of each spring. Since the microthreads are placed in parallel, the total 
stiffness of the microthreads is the stiffness of one thread multiplied by the number of 
threads. Therefore, Eq. 3 can be re-written as follows by substituting Eq. 4 and 5:  
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 [Eq. 6] 
The following values were assumed from literature and were substituted into Eq. 
6:  
ET = 4.0MPa [19] 
AC = 25,900µm
2 (for hydrated microthreads) [19] 
ro = 60mm [38] 
CUT 
MICROTHREAD 
HEART WALL 
ro 
ri 
View of entire heart 
with threads in 
fiber direction 
Cross-sectional view 
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ri = 43mm (t = 17mm) [87] 
Since the stiffness of the heart is different in the fiber and cross fiber directions, the 
calculations must be performed in both directions using the appropriate value for 
stiffness: 
EH = 90,000Pa in the fiber direction for a heart with right 
ventricular hypertrophy [95] 
EH = 25,000Pa in the cross fiber direction for a heart with right 
ventricular hypertrophy [95] 
The composite stiffness (EC) was taken to be 10% greater than the stiffness of the 
heart wall, which is equal to 99,000Pa in the fiber direction and 27,500Pa in the cross 
fiber direction. It was found that N = 21.8 microthreads in the fiber direction and N = 
11.5 microthreads in the cross fiber direction.  
After calculating the number of microthreads required for the stiffness of the 
composite to be 10% greater than that of the heart wall, the structural properties of the 
mesh were confirmed to ensure that the mesh would reduce the dilatation of the heart 
wall. From basic mechanics: 
εσ ×=
×
== E
A
tT
A
F
total
 [Eq. 7] 
In Eq. 7 σ = stress, F = force, A = area, T = wall tension, t = wall thickness, E = wall 
stiffness, and ε = strain. Simplifying Eq. 7 gives the following: 
AE
tT
×
×
=ε  [Eq. 8] 
In order to decrease the amount of dilatation, the mesh should result in a decrease in the 
strain. In Eq. 8 the wall tension and wall thickness remain constant and therefore in order 
for the strain to decrease, the product of the stiffness and area must increase.  
With the heart wall alone: 
( )2i2oH r - rEAE π=×  [Eq. 9] 
With the addition of the microthread mesh restraint: 
( )[ ]NAr - rEAE C2i2oC +=× π  [Eq. 10] 
The product of stiffness and area was calculated with the heart wall alone and 
with the microthread mesh using Eq. 9 and Eq. 10 and the values were obtained from 
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literature, as described above. In the fiber direction, for the heart wall alone EA is 495.1N 
and with the microthread mesh EA is 544.6N. In the direction perpendicular to the fibers 
(cross fiber direction), for the heart wall alone EA is 137.5N and with the microthread 
mesh EA is 151.3N. In both directions EA has increased and therefore the mesh will be 
able to reduce the dilatation of the heart wall.  
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APPENDIX L-Protocol for Cell Migration Assay 
Cell Migration Assay 
 
Purpose 
 
 
To compare the rate of migration of SMCs to microthreads coated 
in PDGF to uncoated microthreads. 
 
Specifications 
 
 
N/A 
 
Materials and 
Equipment 
 
Materials 
• Silicone elastomer 
• PDMS curing agent 
• Petri dishes 
• 70% ethanol 
• PBS 
• PDGF solution (10ng/mL PDGF-ββ in DMEM + 20% FBS + 
1% pen/strep) 
• Microthreads 
• Sterile silicone glue 
• Cell culture media (DMEM + 10% FBS) 
• 0.25% trypsin 
 
Equipment 
• Vacuum chamber 
• Oven set to 50°C 
• Scalpel 
• Autoclave 
• Sterile hood 
• Inverted light microscope with camera 
• Adobe Photoshop CS2 
 
 
Procedure 
Making PDMS blocks 
1. Mix silicone elastomer and PDMS curing agent in a ratio of 
10:1. 
2. Pour PDMS mixture into petri dishes.  
3. Place in a vacuum chamber to remove air bubbles. 
4. Place in an oven set to 50°C for approximately 2 hours. 
5. Remove the PDMS from the petri dish and cut in half with a 
scalpel. (The diameter is 8.5cm so the PDMS should be cut at 
4.25cm.) Remove the ends of the half circles with a scalpel by 
cutting 2cm from the ends of the half circles. 
6. Sterilize the PDMS blocks in an autoclave. 
Microthread preparation 
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1. Sterilize microthreads in 70% ethanol for 24 hours. 
2. Wash microthreads in sterile PBS three times for 5 minutes per 
wash. 
3. For PDGF coated microthreads, place the threads in the PDGF 
solution for 24 hours and subsequently wash the threads in PBS 
3 times for 5 minutes per wash.  
Performing the cell migration assay 
1. Attach the microthreads to one side of the petri dish using 
sterile silicone glue. 
2. Draw gridlines on the cover of the petri dish, as outlined 
below: 
 
3. Place the PDMS blocks in the petri dish under the sterile hood. 
4. Trypsinize cells and count them using a hemocytometer. 
5. Culture SMCs on the side of the plate opposite the 
microthreads placing ~50,000 cells on each plate.  
6. Allow the cells to plate down for 24 hours. 
7. Aspirate the media to remove any floating cells. 
8. Remove the PDMS block and add fresh media.  
9. Visualize the plate using an inverted light microscope with a 
camera adapter to observe the migration and proliferation of 
the cells. 
10. Take pictures of each plate at the intersection of each grid line.  
11. Stitch the pictures together using Adobe Photoshop CS2. 
  
 
Expected 
Results 
 
 
The cells cultured in the plates with PDGF coated microthreads 
will migrate more quickly than cells cultured with control samples.  
 
 
Methods of 
Analysis 
 
N/A 
8.5cm 
4.25cm   1cm 1cm  1cm 1.5cm 
2cm 
2cm 
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